###begin article-title 0
###xml 4 5 1 2 <sub xmlns:xlink="http://www.w3.org/1999/xlink">3</sub>
beta3 Integrin and Src facilitate transforming growth factor-beta mediated induction of epithelial-mesenchymal transition in mammary epithelial cells
###end article-title 0
###begin p 1
This is an open access article distributed under the terms of the Creative Commons Attribution License (), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
###end p 1
###begin title 2
Introduction
###end title 2
###begin p 3
Transforming growth factor (TGF)-beta suppresses breast cancer formation by preventing cell cycle progression in mammary epithelial cells (MECs). During the course of mammary tumorigenesis, genetic and epigenetic changes negate the cytostatic actions of TGF-beta, thus enabling TGF-beta to promote the acquisition and development of metastatic phenotypes. The molecular mechanisms underlying this conversion of TGF-beta function remain poorly understood but may involve signaling inputs from integrins.
###end p 3
###begin title 4
Methods
###end title 4
###begin p 5
###xml 4 6 1 3 <sub xmlns:xlink="http://www.w3.org/1999/xlink">3 </sub>
###xml 115 117 109 111 <sub xmlns:xlink="http://www.w3.org/1999/xlink">3 </sub>
###xml 202 204 193 195 <sub xmlns:xlink="http://www.w3.org/1999/xlink">3 </sub>
###xml 333 335 318 320 <sub xmlns:xlink="http://www.w3.org/1999/xlink">3 </sub>
###xml 400 402 382 384 <sub xmlns:xlink="http://www.w3.org/1999/xlink">3 </sub>
beta3 Integrin expression or function in MECs was manipulated by retroviral transduction of active or inactive beta3 integrins, or by transient transfection of small interfering RNA (siRNA) against beta3 integrin. Altered proliferation, invasion, and epithelial-mesenchymal transition (EMT) stimulated by TGF-beta in control and beta3 integrin manipulated MECs was determined. Src involvement in beta3 integrin mediated alterations in TGF-beta signaling was assessed by performing Src protein kinase assays, and by interdicting Src function pharmacologically and genetically.
###end p 5
###begin title 6
Results
###end title 6
###begin p 7
###xml 34 35 27 28 <sub xmlns:xlink="http://www.w3.org/1999/xlink">v</sub>
###xml 39 41 29 31 <sub xmlns:xlink="http://www.w3.org/1999/xlink">3 </sub>
###xml 140 142 127 129 <sub xmlns:xlink="http://www.w3.org/1999/xlink">3 </sub>
###xml 240 242 218 220 <sub xmlns:xlink="http://www.w3.org/1999/xlink">3 </sub>
###xml 472 474 438 440 <sub xmlns:xlink="http://www.w3.org/1999/xlink">3 </sub>
###xml 602 604 556 558 <sub xmlns:xlink="http://www.w3.org/1999/xlink">3 </sub>
###xml 727 735 675 683 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in vitro</italic>
###xml 798 800 743 745 <sub xmlns:xlink="http://www.w3.org/1999/xlink">3 </sub>
###xml 936 938 872 874 <sub xmlns:xlink="http://www.w3.org/1999/xlink">3 </sub>
###xml 1032 1037 <span type="species:ncbi:9606">human</span>
TGF-beta stimulation induced alphavbeta3 integrin expression in a manner that coincided with EMT in MECs. Introduction of siRNA against beta3 integrin blocked its induction by TGF-beta and prevented TGF-beta stimulation of EMT in MECs. beta3 integrin interacted physically with the TGF-beta receptor (TbetaR) type II, thereby enhancing TGF-beta stimulation of mitogen-activated protein kinases (MAPKs), and of Smad2/3-mediated gene transcription in MECs. Formation of beta3 integrin:TbetaR-II complexes blocked TGF-beta mediated growth arrest and increased TGF-beta mediated invasion and EMT. Dual beta3 integrin:TbetaR-II activation induced tyrosine phosphorylation of TbetaR-II, a phosphotransferase reaction mediated by Src in vitro. Inhibiting Src activity in MECs prevented the ability of beta3 integrin to induce TbetaR-II tyrosine phosphorylation, MAPK activation, and EMT stimulated by TGF-beta. Lastly, wild-type and D119A beta3 integrin expression enhanced and abolished, respectively, TGF-beta stimulation of invasion in human breast cancer cells.
###end p 7
###begin title 8
Conclusion
###end title 8
###begin p 9
###xml 17 19 14 16 <sub xmlns:xlink="http://www.w3.org/1999/xlink">3 </sub>
###xml 226 228 211 213 <sub xmlns:xlink="http://www.w3.org/1999/xlink">3 </sub>
###xml 368 373 <span type="species:ncbi:9606">human</span>
We show that beta3 integrin alters TGF-beta signaling in MECs via Src-mediated TbetaR-II tyrosine phosphorylation, which significantly enhanced the ability of TGF-beta to induce EMT and invasion. Our findings suggest that beta3 integrin interdiction strategies may represent an innovative approach to re-establishing TGF-beta mediated tumor suppression in progressing human breast cancers.
###end p 9
###begin title 10
Introduction
###end title 10
###begin p 11
###xml 621 622 600 601 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B1">1</xref>
###xml 950 951 923 924 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B2">2</xref>
###xml 952 953 925 926 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B5">5</xref>
###xml 1220 1221 1187 1188 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B6">6</xref>
###xml 1041 1047 <span type="species:ncbi:9606">humans</span>
Transforming growth factor (TGF)-beta is a powerful tumor suppressor that prevents the uncontrolled proliferation of epithelial, endothelial, and hematopoietic cells. In doing so, TGF-beta initiates transmembrane signaling by activating its type I and type II serine/threonine kinase receptors (TGF-beta receptor TbetaR-I and TbetaR-II, respectively). Following its transphosphorylation and stimulation by TbetaR-II, TbetaR-I then binds, phosphorylates, and activates the intracellular effectors Smad2 and Smad3, which subsequently complex with Smad4 and translocate to the nucleus to regulate target gene transcription [1]. Although the Smad pathway is by far the most characterized TGF-beta activated pathway, TGF-beta also governs cell physiology through activation of mitogen-activated protein kinases (MAPKs; including extracellular signal-regulated kinase [ERK]1/2, p38, and c-Jun amino-terminal kinase) and of phosphoinositol-3 kinase (PI3K) [2-5]. Aberrant activation of MAPKs and PI3K often is associated with cancer development in humans. Precisely how TGF-beta activates these alternative pathways and how these signals are integrated into the biology and pathology of TGF-beta remain to be elucidated fully [6].
###end p 11
###begin p 12
###xml 57 58 54 55 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B7">7</xref>
###xml 59 61 56 58 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B10">10</xref>
###xml 586 588 574 576 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B11">11</xref>
###xml 707 708 692 693 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B1">1</xref>
###xml 709 710 694 695 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B6">6</xref>
###xml 711 712 696 697 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B8">8</xref>
###xml 713 715 698 700 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B12">12</xref>
###xml 716 718 701 703 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B13">13</xref>
###xml 927 928 912 913 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B2">2</xref>
###xml 929 930 914 915 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B3">3</xref>
###xml 931 933 916 918 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B14">14</xref>
###xml 934 936 919 921 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B16">16</xref>
###xml 1152 1153 1134 1135 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B8">8</xref>
###xml 1154 1156 1136 1138 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B17">17</xref>
TGF-beta plays a dual role during mammary tumorigenesis [7-10]. For instance, TGF-beta normally prohibits mammary epithelial cell (MEC) cell cycle progression, and consequently suppresses MEC tumorigenesis. However, during the course of mammary tumorigenesis, TGF-beta signaling becomes dysregulated and uncoupled from regulation of cell cycle progression. More importantly, altered TGF-beta signaling actively contributes to the acquisition and development of metastatic phenotypes, in part through its ability to stimulate epithelial-mesenchymal transitions (EMTs) in cancerous MECs [11]. Indeed, recent evidence suggests that TGF-beta suppresses tumorigenesis largely via Smad2/3-mediated growth arrest [1,6,8,12,13], whereas its ability to promote tumorigenesis and EMT occurs via the integration of Smad2/3 signals with those arising in response to activation of RhoA, MAPKs (e.g. ERK1/2 and p38 MAPK), and PI3K pathways [2,3,14-16]. Thus, breast cancer cells have developed effective strategies for circumventing the tumor suppressing activities of TGF-beta, while simultaneously selecting for, or even enhancing, its tumor promoting activities [8,17].
###end p 12
###begin p 13
###xml 339 341 333 335 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B18">18</xref>
###xml 458 460 449 451 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B11">11</xref>
Apart from playing a prominent role in preventing cell cycle progression, TGF-beta also is a major regulator of cell microenvironments and extracellular matrix (ECM) remodeling. TGF-beta alters cell microenvironments in part through its ability to induce the expression of unique subsets of integrins as well as that of their ECM ligands [18]. In doing so, TGF-beta enables malignant cells to undergo EMT and, consequently, to escape their tissue of origin [11].
###end p 13
###begin p 14
###xml 119 121 119 121 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B19">19</xref>
###xml 398 400 398 400 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B20">20</xref>
###xml 401 403 401 403 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B22">22</xref>
###xml 590 592 590 592 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B23">23</xref>
###xml 593 595 593 595 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B24">24</xref>
###xml 629 630 625 626 <sub xmlns:xlink="http://www.w3.org/1999/xlink">v</sub>
###xml 634 635 627 628 <sub xmlns:xlink="http://www.w3.org/1999/xlink">3</sub>
###xml 835 837 828 830 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B23">23</xref>
###xml 838 840 831 833 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B25">25</xref>
###xml 1002 1004 992 994 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B26">26</xref>
###xml 1005 1007 995 997 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B27">27</xref>
###xml 1038 1039 1024 1025 <sub xmlns:xlink="http://www.w3.org/1999/xlink">v</sub>
###xml 1043 1045 1026 1028 <sub xmlns:xlink="http://www.w3.org/1999/xlink">3 </sub>
###xml 1178 1180 1161 1163 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B25">25</xref>
###xml 1181 1183 1164 1166 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B27">27</xref>
###xml 1184 1186 1167 1169 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B31">31</xref>
###xml 1473 1475 1447 1449 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B32">32</xref>
###xml 1476 1478 1450 1452 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B33">33</xref>
Integrins are heterodimeric transmembrane receptors that bind ECM ligands and couple cells to their microenvironments [19]. Most integrins initiate transmembrane signaling by activating focal adhesion kinase (FAK) and Src family kinases at adhesive sites. FAK and Src further recruit and activate various downstream effectors, such as PI3K and members of the Ras and Rho families of small GTPases [20-22]. Integrins also interact with and couple to receptor tyrosine kinases (RTKs) to promote cell survival, proliferation, and migration in response to soluble growth factors and cytokines [23,24]. One such integrin, namely alphavbeta3, binds to arginine-glycine-aspartic acid (RGD) amino acid containing components of the ECM, such as vitronectin, fibronectin, and osteopontin, and mediates RTK activation of MAPKs and cell invasion [23-25]. Similar to the effects of tumorigenesis on TGF-beta signaling, integrin expression is altered during tumorigenesis, including developing tumors of the breast [26,27]. In particular, altered alphavbeta3 integrin expression correlates with mammary tumorigenesis, particularly the processes of breast cancer cell invasion and metastasis [25,27-31], raising the possibility that differential integrin expression may contribute to the tumor promoting activities of TGF-beta. Indeed, TGF-beta stimulated EMT is abrogated by treatments that inhibit MEC integrin adhesion, suggesting a need for integrins in mediating TGF-beta signaling [32,33].
###end p 14
###begin p 15
###xml 140 142 134 136 <sub xmlns:xlink="http://www.w3.org/1999/xlink">3 </sub>
###xml 362 363 346 347 <sub xmlns:xlink="http://www.w3.org/1999/xlink">v</sub>
###xml 367 369 348 350 <sub xmlns:xlink="http://www.w3.org/1999/xlink">3 </sub>
###xml 454 456 429 431 <sub xmlns:xlink="http://www.w3.org/1999/xlink">3 </sub>
###xml 561 563 530 532 <sub xmlns:xlink="http://www.w3.org/1999/xlink">3 </sub>
###xml 779 781 739 741 <sub xmlns:xlink="http://www.w3.org/1999/xlink">3 </sub>
###xml 811 813 768 770 <sub xmlns:xlink="http://www.w3.org/1999/xlink">3 </sub>
###xml 1052 1054 997 999 <sub xmlns:xlink="http://www.w3.org/1999/xlink">3 </sub>
###xml 1326 1327 1262 1263 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B9">9</xref>
###xml 1361 1363 1294 1296 <sub xmlns:xlink="http://www.w3.org/1999/xlink">3 </sub>
###xml 1435 1437 1365 1367 <sub xmlns:xlink="http://www.w3.org/1999/xlink">3 </sub>
###xml 1659 1661 1583 1585 <sub xmlns:xlink="http://www.w3.org/1999/xlink">3 </sub>
###xml 215 221 <span type="species:ncbi:10090">murine</span>
###xml 1271 1276 <span type="species:ncbi:9606">human</span>
To further investigate the role of altered integrin expression in regulating the MEC response to TGF-beta, we determined the effects of beta3 integrin expression on the ability of TGF-beta to regulate NMuMG (normal murine mammary gland) cell proliferation, invasion, and EMT. We found that treatment of NMuMG cells with TGF-beta induced their expression of alphavbeta3 integrin, an event that coincided with TGF-beta stimulation of EMT. Accordingly, beta3 integrin deficiency abolished the ability of TGF-beta to induce EMT in MECs. Moreover, we found that beta3 integrin interacted physically with TbetaR-II at the cell surface, leading to conversion of TGF-beta from a suppressor of NMuMG cell growth to a promoter of their invasiveness and EMT. Mechanistically, activated beta3 integrin recruited Src to beta3 integrin:TbetaR-II complexes, where it tyrosine phosphorylated TbetaR-II, leading to enhanced activation of MAPKs and induction of EMT stimulated by TGF-beta. Importantly, abolishing Src activity or expression in NMuMG cells prevented beta3 integrin-mediated tyrosine phosphorylation of TbetaR-II and, consequently, EMT stimulated by TGF-beta. Finally, we found that the acquisition of a metastatic phenotype in MCF10A derivatives, which serve as a model of human breast cancer progression regulated by TGF-beta [9], coincided with upregulated beta3 integrin and FAK expression. Similar to its effects in NMuMG cells, beta3 integrin expression significantly enhanced TGF-beta mediated stimulation of cell invasion in benign MCF10A cells as well as in their highly metastatic counterparts MCF10CA1a cells. Importantly, the expression of D119A beta3 integrin in these metastatic cells completely abolished the ability of TGF-beta to induce MCF10CA1a cell invasion.
###end p 15
###begin p 16
###xml 89 91 86 88 <sub xmlns:xlink="http://www.w3.org/1999/xlink">3 </sub>
###xml 323 328 <span type="species:ncbi:9606">human</span>
Taken together, our findings identify a novel convergence point in MECs that enables beta3 integrins to override the tumor suppressing activities of TGF-beta, suggesting that integrin interdiction strategies may one day represent an innovative approach to re-establishing TGF-beta mediated tumor suppression in progressing human breast cancers.
###end p 16
###begin title 17
Materials and methods
###end title 17
###begin title 18
Retroviral plasmids and expression
###end title 18
###begin p 19
###xml 44 46 41 43 <sub xmlns:xlink="http://www.w3.org/1999/xlink">3 </sub>
###xml 240 242 235 237 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B34">34</xref>
###xml 261 263 253 255 <sub xmlns:xlink="http://www.w3.org/1999/xlink">3 </sub>
###xml 352 355 344 347 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Bgl</italic>
###xml 379 382 371 374 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Xho</italic>
###xml 692 694 684 686 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B35">35</xref>
###xml 704 706 693 695 <sub xmlns:xlink="http://www.w3.org/1999/xlink">3 </sub>
###xml 34 39 <span type="species:ncbi:9606">human</span>
###xml 563 569 <span type="species:ncbi:10090">murine</span>
The cDNAs encoding wild-type (WT) human beta3 integrin, as well as its inactive mutant D119A (D-->A point mutation at position 119), were generously provided by Dr Mark H Ginsberg (University of California at San Diego, San Diego, CA, USA [34]). Retroviral beta3 integrin vectors were synthesized by PCR amplification using oligonucleotides containing BglII (amino terminus) and XhoI (carboxyl terminus) restriction sites, and subsequently ligated into identical sites immediately upstream of the IRES in the bicistronic retroviral vector pMSCV-IRES-GFP (plasmid murine stem cell virus-internal ribosomal entry site-green fluorescent protein) or pMSCV-IRES-YFP (yellow fluorescent protein). [35] All beta3 integrin inserts were sequenced in their entirety on an Applied Biosystems 377A DNA sequencing machine (Applied Biosystems, Foster City, CA USA).
###end p 19
###begin p 20
###xml 138 142 138 142 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Hind</italic>
###xml 167 170 167 170 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Xba</italic>
###xml 383 384 383 384 <sub xmlns:xlink="http://www.w3.org/1999/xlink">6</sub>
###xml 684 687 684 687 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Eco</italic>
###xml 711 714 711 714 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Bgl</italic>
###xml 12 17 <span type="species:ncbi:9606">human</span>
Full-length human c-Src cDNA was PCR amplified from IMAGE clone 4871614 (Invitrogen, Carlsbad, CA, USA) using oligonucleotides containing HindIII (amino terminus) and XbaI (carboxyl terminus) restriction sites, respectively. The resulting PCR product was ligated into corresponding sites in pcDNA3.1/Myc-His B vector (Invitrogen) to carboxyl-terminally tag c-Src with a Myc and (His)6-tag. Kinase dead (Lys295Met) or constitutively active (Tyr530Phe) c-Src mutants were generated by site-directed mutagenesis using the QuikChange site-directed mutagenesis kit (Stratagene, La Jolla, CA, USA). Afterward, Myc-His tagged WT and mutant c-Src cDNAs were amplified by PCR and ligated into EcoRI (amino terminus) and BglII (carboxyl terminus) restriction sites in pMSCV-IRES-GFP. All c-Src inserts sequenced in their entirety on an Applied Biosystems 377A DNA sequencing machine.
###end p 20
###begin p 21
###xml 200 201 199 200 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B9">9</xref>
###xml 240 242 236 238 <sub xmlns:xlink="http://www.w3.org/1999/xlink">3 </sub>
###xml 423 425 416 418 <sub xmlns:xlink="http://www.w3.org/1999/xlink">3 </sub>
###xml 579 581 572 574 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B36">36</xref>
###xml 847 849 837 839 <sub xmlns:xlink="http://www.w3.org/1999/xlink">3 </sub>
###xml 986 988 973 975 <sub xmlns:xlink="http://www.w3.org/1999/xlink">3 </sub>
###xml 1159 1161 1143 1145 <sub xmlns:xlink="http://www.w3.org/1999/xlink">3 </sub>
###xml 92 98 <span type="species:ncbi:9913">bovine</span>
NMuMG cells were cultured in Dulbecco's modified Eagle's medium supplemented with 10% fetal bovine serum (FBS) and 10 mug/ml insulin. MCF10A and MCF10CA1a cells were cultured as previously described [9]. Stable expression of individual beta3 integrin subunits or c-Src derivatives in NMuMG and MCF10A cells was accomplished by their overnight infection with control (i.e. pMSCV-IRES-GFP or pMSCV-IRES-YFP), WT or D119A beta3 integrin, or mutant c-Src retroviral supernatants produced by EcoPac2 retroviral packaging cells (Clontech, San Diego, CA, USA), as described previously [36]. Cells expressing GFP, YFP, or both fluorescent proteins were isolated and collected 48 hours later on a MoFlo cell sorter (Cytomation, Fort Collins, CO, USA), and subsequently were expanded to yield stable polyclonal populations of control (i.e. GFP or YFP), beta3 integrin (i.e. WT or D119A), or mutant c-Src (i.e. kinase-dead or constitutively active) expressing cells. Expression of recombinant beta3 integrins in individual NMuMG cell lines was monitored by immunoblotting detergent solubilized whole cell extracts with antibodies against the extracellular domain of beta3 integrin (Santa Cruz Biotechnology, Santa Cruz, CA, USA), whereas expression of mutant c-Src protein kinases was detected by immunoblotting with either anti-Src (1:1000 dilution; Santa Cruz Biotechnology) or anti-Myc (1:1000 dilution; Covance, Princeton, New Jersey USA) antibodies.
###end p 21
###begin title 22
Fluorescence-activated cell sorting analysis
###end title 22
###begin p 23
###xml 32 34 29 31 <sub xmlns:xlink="http://www.w3.org/1999/xlink">3 </sub>
###xml 118 120 112 114 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1 </sub>
###xml 178 180 172 174 <sup xmlns:xlink="http://www.w3.org/1999/xlink">6 </sup>
###xml 413 415 403 405 <sub xmlns:xlink="http://www.w3.org/1999/xlink">v </sub>
###xml 492 494 479 481 <sub xmlns:xlink="http://www.w3.org/1999/xlink">3 </sub>
###xml 714 716 697 699 <sub xmlns:xlink="http://www.w3.org/1999/xlink">v </sub>
###xml 723 725 703 705 <sub xmlns:xlink="http://www.w3.org/1999/xlink">3 </sub>
###xml 282 288 <span type="species:ncbi:9913">bovine</span>
###xml 402 407 <span type="species:ncbi:10090">mouse</span>
###xml 482 487 <span type="species:ncbi:9606">human</span>
Control (GFP), WT, or D119A beta3 integrin expressing NMuMG cells were cultured in the absence or presence of TGF-beta1 (5 ng/ml) for 36 hours to stimulate EMT. Afterward, 1 x 106 cells were trypsinized, washed, and incubated in fluorescence-activated cell sorter (FACS) buffer (1% bovine serum albumen in phosphate-buffered saline [PBS]) supplemented with a 1:20 dilution of either PE-conjugated anti-mouse alphav integrin (BD Pharmingen, San Diego, CA, USA) or PE-conjugated anti-human beta3 integrin antibodies (BD Pharmingen). After a 30 min incubation on ice, the cells were washed twice in PBS and immediately fixed with 1% paraformaldehyde before fluorescence-activated cell sorting (FACS) analysis of alphav or beta3 expression in GFP-positive NMuMG cells.
###end p 23
###begin title 24
Immunofluorescence studies
###end title 24
###begin p 25
###xml 116 118 113 115 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B37">37</xref>
###xml 119 121 116 118 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B38">38</xref>
###xml 148 150 142 144 <sub xmlns:xlink="http://www.w3.org/1999/xlink">3 </sub>
###xml 323 325 314 316 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1 </sub>
###xml 401 403 383 385 <sub xmlns:xlink="http://www.w3.org/1999/xlink">3 </sub>
###xml 464 466 443 445 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1 </sub>
###xml 928 929 900 901 <sub xmlns:xlink="http://www.w3.org/1999/xlink">v</sub>
###xml 933 935 902 904 <sub xmlns:xlink="http://www.w3.org/1999/xlink">3 </sub>
###xml 1102 1103 1063 1064 <sub xmlns:xlink="http://www.w3.org/1999/xlink">v</sub>
###xml 1107 1109 1065 1067 <sub xmlns:xlink="http://www.w3.org/1999/xlink">3 </sub>
###xml 980 984 <span type="species:ncbi:9925">goat</span>
###xml 1201 1205 <span type="species:ncbi:9925">goat</span>
###xml 1211 1216 <span type="species:ncbi:10090">mouse</span>
The ability of TGF-beta to alter actin cytoskeletal architecture was monitored essentially as described previously [37,38]. Briefly, control or beta3 integrin expressing NMuMG cells (30,000 cells/well) were plated onto gelatin coated (0.1% in PBS) glass coverslips in 24-well plates. The cells were stimulated with TGF-beta1 (5 ng/ml) for 0-36 hours at 37degreesC. In some experiments, control or beta3 integrin-expressing NMuMG cells were stimulated with TGF-beta1 in the absence or presence of the Src kinase inhibitor PP2 (10 mumol/l; Calbiochem, Temecula, CA, USA) or its inactive counterpart PP3 (10 mumol/l; Calbiochem). Upon completion of agonist stimulation, the cells were washed in PBS, fixed in 4% paraformaldehyde, and permeabilized by Triton X-100 (0.2% in PBS). The cells were then blocked in PBS supplemented with 1.5% FBS, followed by incubation with TRITC-phalloidin or FITC-phalloidin (0.25 mumol/l). For alphavbeta3 integrin staining, the cells were blocked in goat beta-globulin (200 mug/ml; Jackson Immunoresearch, West Grove, PA, USA) before sequential incubations with anti-alphavbeta3 LM609 antibody (1:250 dilution; BD Biosciences, San Jose, CA USA), followed by biotinylated goat anti-mouse antibody (5 mug/ml; Jackson Immunoresearch) and finally by Alexa-streptavidin (1.2 mug/ml; Invitrogen). All images were captured on a Nikon Diaphot microscope.
###end p 25
###begin title 26
RNA interference studies
###end title 26
###begin p 27
###xml 31 33 28 30 <sub xmlns:xlink="http://www.w3.org/1999/xlink">3 </sub>
###xml 540 542 534 536 <sub xmlns:xlink="http://www.w3.org/1999/xlink">3 </sub>
###xml 654 656 645 647 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1 </sub>
###xml 913 917 898 902 <italic xmlns:xlink="http://www.w3.org/1999/xlink">GLO </italic>
NMuMG cells lacking either beta3 integrin or c-Src were generated using SMARTpool small interfering RNAs (siRNAs), in accordance with the manufacturer's recommendations (Dharmacon, Lafayette, CO, USA). Briefly, NMuMG cells (30,000 cells/well) were plated either onto plastic or gelatin coated (0.1% in PBS) glass coverslips in 24-well plates and cultured overnight in antibiotic-free media. Fresh media was added the following morning and the cells were transiently transfected with DharmaFECT One reagent (Dharmacon) supplemented with beta3 integrin or c-Src siRNAs (100 nmol/l). Thirty-six hours after transfection, the cells were treated with TGF-beta1 (5 ng/ml) for varying times at 37degreesC. Upon completion of agonist stimulation, the cells were harvested and prepared for immunoblotting and immunofluorescence analyses as above. NMuMG cell transfection efficiency was monitored by co-transfection with siGLO RISC-Free siRNA (Dharmacon), which was visualized under fluorescent microscope.
###end p 27
###begin title 28
Cellular phosphorylation assays
###end title 28
###begin p 29
###xml 15 17 12 14 <sub xmlns:xlink="http://www.w3.org/1999/xlink">3 </sub>
###xml 309 311 303 305 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1 </sub>
###xml 763 765 752 754 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B36">36</xref>
###xml 1393 1395 1379 1381 <sub xmlns:xlink="http://www.w3.org/1999/xlink">3 </sub>
###xml 1507 1508 1490 1491 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B5">5</xref>
###xml 1509 1511 1492 1494 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B32">32</xref>
###xml 1512 1514 1495 1497 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B39">39</xref>
###xml 1753 1754 1733 1734 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B5">5</xref>
###xml 1755 1757 1735 1737 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B32">32</xref>
###xml 1758 1760 1738 1740 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B39">39</xref>
Control or beta3 integrin-expressing NMuMG cells were cultured onto 24-well plates (30,000 cells/well) and allowed to adhere overnight. The next morning, the cells were washed twice in PBS and placed in Dulbecco's modified Eagle's medium supplemented with 0.5% FBS for 4 hours before stimulation with TGF-beta1 (5 ng/ml) for 0-120 min. In some experiments, the cells were stimulated with Prolactin (100 ng/ml; generously provided by National Hormone and Peptide Program, US National Institutes of Health), 4alpha-phorbol 12-myristate 13-acetate (PMA; 10 ng/ml; Sigma, St. Louis, MO, USA), or epidermal growth factor (EGF; 100 ng/ml; Upstate, Charlottesville, VA). Afterward, the cells were washed in ice-cold PBS and lysed in 200 mul of buffer H/1% Triton X-100 [36]. Detergent solubilized whole cell extracts were prepared, clarified by microcentrifugation, and subsequently concentrated by acetone precipitation. Recovered proteins were fractionated through 10% SDS-PAGE gels, immobilized electrophoretically to nitrocellulose membranes, and subsequently probed with a 1:250 dilution of either anti-phospho-Smad2, -ERK1/2, or -p38 MAPK polyclonal antibodies (Cell Signaling Technology, Beverly, MA, USA). The resulting immunocomplexes were visualized by enhanced chemiluminescence. Differences in protein loading could not be readily monitored by b-actin immunoreactivity because stable beta3 integrin expression and TGF-beta stimulation significantly elevated b-actin expression in MECs (data not shown [5,32,39]). Thus, differences in protein loading were instead monitored by reprobing stripped membranes with anti-ERK1/2 antibodies (1:2500 dilution; Upstate, Charlottesville, VA USA), whose expression in MECs was unaltered by TGF-beta treatment [5,32,39].
###end p 29
###begin title 30
Cell biological assays
###end title 30
###begin p 31
###xml 31 33 28 30 <sub xmlns:xlink="http://www.w3.org/1999/xlink">3 </sub>
###xml 179 180 173 174 <sup xmlns:xlink="http://www.w3.org/1999/xlink">3</sup>
###xml 237 239 231 233 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B35">35</xref>
###xml 450 452 444 446 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B35">35</xref>
###xml 453 455 447 449 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B40">40</xref>
###xml 579 581 573 575 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B35">35</xref>
The effect of WT and D119A beta3 integrin expression on various TGF-beta stimulated activities in MECs was determined as follows: cell proliferation using 10,000 cells/well in a [3H]thymidine incorporation assay, as described elsewhere [35]; cell invasion induced by 10% serum using 350,000 cells/well in a modified Boyden-chamber coated with Matrigel matrices (diluted 1:25 in serum-free Dulbecco's modified Eagle's medium), as described elsewhere [35,40]; and gene expression using 30,000 cells/well in a synthetic pSBE-luciferase reporter gene assay, as described previously [35].
###end p 31
###begin title 32
###xml 41 43 38 40 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1 </sub>
Iodinated transforming growth factor-beta1 radioligand binding and cross-linking assay
###end title 32
###begin p 33
###xml 16 18 13 15 <sub xmlns:xlink="http://www.w3.org/1999/xlink">3 </sub>
###xml 171 174 168 171 <sup xmlns:xlink="http://www.w3.org/1999/xlink">125</sup>
###xml 184 186 178 180 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1 </sub>
###xml 253 255 247 249 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B41">41</xref>
###xml 445 447 436 438 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B41">41</xref>
###xml 603 605 591 593 <sub xmlns:xlink="http://www.w3.org/1999/xlink">3 </sub>
###xml 644 646 629 631 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1 </sub>
Control and beta3 integrin-expressing NMuMG cells were plated onto 10 cm plates and grown until they reached 90% confluency. The radioligand binding and cross-linking of [125I]TGF-beta1 (200 pmol/l) to NMuMG cells was performed as described previously [41]. Afterward, cytokine:receptor complexes contained in detergent-solubilized whole cell extracts were isolated by immunoprecipitation with anti-TbetaR-II antibodies, as described elsewhere [41]. Immunocomplexes were subsequently fractionated through 7.5% SDS-PAGE and then immobilized electrophoretically to nitrocellulose and probed with anti-beta3 integrin antibodies. Iodinated TGF-beta1 bound to cell surface TbetaR-I and TbetaR-II was visualized by exposure of the dried nitrocellulose membranes to a phosphor screen, which was developed 1-3 days later on a Molecular Dynamics Typhoon Scanner (GE Healthcare Bio-Sciences Corp., Piscataway, NJ USA).
###end p 33
###begin title 34
Integrin:TbetaR-II co-immunoprecipitation assays
###end title 34
###begin p 35
###xml 17 18 17 18 <sup xmlns:xlink="http://www.w3.org/1999/xlink">6</sup>
###xml 27 29 24 26 <sub xmlns:xlink="http://www.w3.org/1999/xlink">3 </sub>
###xml 45 46 42 43 <sup xmlns:xlink="http://www.w3.org/1999/xlink">5</sup>
###xml 144 146 138 140 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1 </sub>
###xml 518 520 511 513 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B42">42</xref>
###xml 711 713 701 703 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1 </sub>
###xml 800 802 787 789 <sub xmlns:xlink="http://www.w3.org/1999/xlink">3 </sub>
###xml 1028 1030 1009 1011 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B43">43</xref>
###xml 1346 1348 1318 1320 <sub xmlns:xlink="http://www.w3.org/1999/xlink">3 </sub>
Control (2.5 x 106) or beta3 integrin (7 x 105) expressing NMuMG cells were cultured onto 10 cm plates and subsequently stimulated with TGF-beta1 (5 ng/ml) for varying times in the absence or presence of the Src inhibitor PP2 (10 mumol/l). In some cases, NMuMG cells were held in suspension and replated onto culture dishes previously coated with vitronectin (1 ng/ml; Chemicon, Temecula, CA, USA). Following agonist stimulation, the cells were washed twice in ice-cold PBS and disrupted in Nonidet P-40 lysis buffer [42] (Nonidet P-40; Sigma). The resulting detergent-solubilized whole cell extracts were clarified by microcentrifugation and subjected to the following immunoprecipitation conditions: anti-beta1 integrin antibodies (Santa Cruz Biotechnology) using 1 mg whole cell extract; anti-beta3 integrin antibodies using 1 mg whole cell extract; anti-phosphotyrosine 4G10 antibodies (Upstate) using 1 mg whole cell extract; or anti-TbetaR-I or -TbetaR-II antibodies using 2 mg whole cell extract as described previously [43]. All immunoprecipitations were incubated for 16 hours at 4degreesC with slow rotation. The resulting immunocomplexes were collected by microcentrifugation, washed, fractionated through 10% SDS-PAGE gels, and transferred electrophoretically to nitrocellulose membranes, which subsequently were probed with anti-beta3 integrin (1:1000), anti-TbetaR-II (1:1500; Santa Cruz Biotechnology), or anti-phosphotyrosine 4G10 (1:1500; Upstate) antibodies.
###end p 35
###begin title 36
###xml 0 9 0 9 <italic xmlns:xlink="http://www.w3.org/1999/xlink">In vitro </italic>
In vitro tyrosine kinase phosphorylation assays
###end title 36
###begin p 37
###xml 62 71 59 68 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in vitro </italic>
###xml 187 188 184 185 <italic xmlns:xlink="http://www.w3.org/1999/xlink">S</italic>
###xml 580 582 564 566 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B44">44</xref>
###xml 700 702 678 680 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B44">44</xref>
Tyrosine phosphorylation of TbetaR-II was determined using an in vitro protein kinase assay that measured the ability of either active FAK or Src to phosphorylate recombinant glutathione S-transferase (GST)-TbetaR-II, which contained only the cytoplasmic domain (i.e. the carboxyl terminal 380 amino acids) of TbetaR-II fused to GST. Protein kinase reactions were performed in a final volume of 30 mul, consisting of 1 mug of GST-TbetaR-II with either 0.2 mug of FAK or 1 Unit of Src (Cell Signaling Technology). Reactions were initiated by addition of 10 mul of 4x assay buffer [44] and were incubated for 30 min at 30degreesC. Afterward, the reactions were stopped by addition of 4x sample buffer [44] and boiled for 5 min. Reactions were diluted by addition of 1 ml buffer H/Triton X-100 and immunoprecipitated overnight with anti-TbetaR-II antibodies. The resulting immunocomplexes were collected, washed, and resuspended in 1X sample buffer. GST fusion proteins were fractionated through 10% SDS-PAGE before their immobilization to nitrocellulose membranes. Tyrosine phosphorylation of GST-TbetaR-II was visualized by immunoblotting nitrocellulose membranes with anti-phosphotyrosine antibodies. Differences in immunoprecipitation efficiency and loading were monitored by reprobing stripped membranes with anti-TbetaR-II antibodies.
###end p 37
###begin title 38
Recombinant GST-Smad3 phosphorylation assay
###end title 38
###begin p 39
###xml 122 124 119 121 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B45">45</xref>
###xml 323 325 310 312 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1 </sub>
###xml 1039 1041 993 995 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B43">43</xref>
The phosphorylation of recombinant Smad3 by activated TbetaR complexes was performed essentially as described previously [45]. Briefly, quiescent NMuMG cells were pretreated with 10 mumol/l of either PP2 or SU6656 (EMD Biosciences, La Jolla, CA, USA) for 1 hour at 37degreesC, and subsequently were stimulated with TGF-beta1 (5 ng/ml) for 30 min at 37degreesC. Cytokine stimulations were terminated by washing the cells twice in ice-cold PBS, which then were lysed and solubilized on ice in buffer H/1% Triton X-100. The resulting cell extracts (1 mg/tube) were clarified by microcentrifugation, and subsequently were immunoprecipitated with anti-TbetaR-II antibodies for 2 hours at 4degreesC. TbetaR immunocomplexes were recovered by brief centrifugation and subsequently were washed twice in PBS. TbetaR phosphotransferase activity against recombinant GST-Smad3 was measured for 30 min at 30degreesC in a final reaction volume of 40 mul consisting of 30 mul of TGF-beta receptor complexes, 5 mg GST-Smad3, and 10 mul of 4X assay buffer [43]. Phosphotransferase reactions were stopped by the addition of 4X sample buffer and were boiled for 5 min before their fractionation through 10% SDS-PAGE. Fractionated proteins were immobilized electrophoretically to nitrocellulose membranes, which subsequently were probed with anti-phospho-Smad2/3 antibodies to visualize phosphorylated GST-Smad3. Differences in immunoprecipitation efficiency and loading were monitored by reprobing stripped membranes with anti-TbetaR-II antibodies.
###end p 39
###begin title 40
Results
###end title 40
###begin title 41
###xml 8 10 5 7 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1 </sub>
###xml 51 52 44 45 <sub xmlns:xlink="http://www.w3.org/1999/xlink">v</sub>
###xml 56 58 46 48 <sub xmlns:xlink="http://www.w3.org/1999/xlink">3 </sub>
###xml 86 88 73 75 <sub xmlns:xlink="http://www.w3.org/1999/xlink">3 </sub>
TGF-beta1 mediated EMT increases cell surface alphavbeta3 integrin expression and beta3 integrin:TbetaR-II complex formation in NMuMG cells
###end title 41
###begin p 42
###xml 159 161 159 161 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B46">46</xref>
###xml 162 164 162 164 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B47">47</xref>
###xml 201 203 201 203 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B27">27</xref>
###xml 242 244 239 241 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B48">48</xref>
###xml 401 403 395 397 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B32">32</xref>
###xml 643 645 631 633 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1 </sub>
###xml 751 753 739 741 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B38">38</xref>
###xml 887 889 875 877 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F1">1a</xref>
###xml 921 922 906 907 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1</sub>
###xml 1052 1054 1037 1039 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F1">1a</xref>
###xml 591 596 <span type="species:ncbi:10090">mouse</span>
Alterations in cell microenvironments and stromal compartments play critical roles in regulating the progression of tumors from indolent to aggressive states [46,47]. Differential integrin expression [27] and dysregulated TGF-beta signaling [48] both contribute to the remodeling of cancer cell microenvironments, particularly those of the breast. Because integrins regulate MEC response to TGF-beta [32], we hypothesized that differential integrin expression induced by TGF-beta would contribute to its regulation of MEC proliferation and EMT. To test this hypothesis, we stimulated normal mouse mammary epithelial (NMuMG) cells with TGF-beta1 and monitored changes in actin stress fiber formation by immunofluorescence. As we have shown previously [38], resting NMuMG cells exhibited typical cuboidal epithelial cell morphology characterized by strong cortical acting staining (Figure 1a). When stimulated with TGF-beta1, these cells underwent EMT and exhibited significant formation of actin stress fibers that emanated from focal adhesions (Figure 1a).
###end p 42
###begin p 43
###xml 13 14 9 10 <sub xmlns:xlink="http://www.w3.org/1999/xlink">v</sub>
###xml 18 20 11 13 <sub xmlns:xlink="http://www.w3.org/1999/xlink">3 </sub>
###xml 105 107 98 100 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B27">27</xref>
###xml 108 110 101 103 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B30">30</xref>
###xml 111 113 104 106 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B31">31</xref>
###xml 167 168 153 154 <sub xmlns:xlink="http://www.w3.org/1999/xlink">v</sub>
###xml 172 174 155 157 <sub xmlns:xlink="http://www.w3.org/1999/xlink">3 </sub>
###xml 258 260 238 240 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1 </sub>
###xml 349 350 325 326 <sub xmlns:xlink="http://www.w3.org/1999/xlink">v</sub>
###xml 354 356 327 329 <sub xmlns:xlink="http://www.w3.org/1999/xlink">3 </sub>
###xml 373 375 346 348 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F1">1a</xref>
###xml 435 436 404 405 <sub xmlns:xlink="http://www.w3.org/1999/xlink">v</sub>
###xml 440 442 406 408 <sub xmlns:xlink="http://www.w3.org/1999/xlink">3 </sub>
###xml 475 477 438 440 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1 </sub>
###xml 498 500 461 463 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F1">1b</xref>
###xml 539 540 498 499 <sub xmlns:xlink="http://www.w3.org/1999/xlink">v</sub>
###xml 544 546 500 502 <sub xmlns:xlink="http://www.w3.org/1999/xlink">3 </sub>
###xml 619 620 568 569 <sub xmlns:xlink="http://www.w3.org/1999/xlink">v</sub>
###xml 624 626 570 572 <sub xmlns:xlink="http://www.w3.org/1999/xlink">3 </sub>
###xml 806 808 746 748 <sub xmlns:xlink="http://www.w3.org/1999/xlink">3 </sub>
###xml 905 907 842 844 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F1">1c</xref>
###xml 923 925 857 859 <sub xmlns:xlink="http://www.w3.org/1999/xlink">3 </sub>
###xml 1063 1065 991 993 <sub xmlns:xlink="http://www.w3.org/1999/xlink">3 </sub>
###xml 1167 1168 1091 1092 <sub xmlns:xlink="http://www.w3.org/1999/xlink">v</sub>
###xml 1172 1174 1093 1095 <sub xmlns:xlink="http://www.w3.org/1999/xlink">3 </sub>
###xml 1264 1266 1182 1184 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F1">1c</xref>
###xml 1283 1285 1198 1200 <sub xmlns:xlink="http://www.w3.org/1999/xlink">3 </sub>
###xml 1350 1352 1262 1264 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1 </sub>
###xml 1370 1372 1282 1284 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F1">1c</xref>
###xml 1416 1418 1325 1327 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1 </sub>
Because alphavbeta3 integrin expression is elevated in breast cancers and enhances cancer cell invasion [27,30,31], we monitored the ability of TGF-beta to alter alphavbeta3 integrin expression in NMuMG cells. Immunofluorescence analysis showed that TGF-beta1 treatment of NMuMG cells significantly induced their cell surface expression of the alphavbeta3 integrin (Figure 1a). Western blot analysis confirmed the upregulation of alphavbeta3 integrin expression upon TGF-beta1 mediated EMT (Figure 1b). The association of upregulated alphavbeta3 integrin expression with TGF-beta stimulation of EMT suggested that alphavbeta3 integrins may play an essential role in facilitating EMT stimulated by TGF-beta. We tested this hypothesis by transiently transfecting NMuMG cells with siRNAs directed against beta3 integrin and subsequently monitored their ability to undergo EMT in response to TGF-beta. Figure 1c shows that beta3 integrin deficiency abolished the ability of TGF-beta to stimulate EMT in NMuMG cells. More importantly, NMuMG cells transfected with beta3 integrin siRNAs only exhibited rudimentary EMT characteristics coordinate with the expression of alphavbeta3 integrins, which exhibit significantly delayed expression in response to TGF-beta (Figure 1c). Moreover, beta3 integrin deficiency failed to alter NMuMG cell expression of beta1 integrins (Figure 1c), indicating that signals arising from beta1 integrin were insufficient in mediating EMT by TGF-beta.
###end p 43
###begin p 44
###xml 116 117 109 110 <sub xmlns:xlink="http://www.w3.org/1999/xlink">v</sub>
###xml 121 123 111 113 <sub xmlns:xlink="http://www.w3.org/1999/xlink">3 </sub>
###xml 221 223 208 210 <sub xmlns:xlink="http://www.w3.org/1999/xlink">3 </sub>
###xml 303 304 287 288 <sub xmlns:xlink="http://www.w3.org/1999/xlink">3</sub>
Collectively, these findings show that TGF-beta induces EMT in NMuMG cells, and that upregulated expression of alphavbeta3 integrin is essential for this process to occur. The findings also raise the possibility that beta3 integrins may play a direct role in regulating various MEC responses to TGF-beta3.
###end p 44
###begin p 45
###xml 92 94 92 94 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B23">23</xref>
###xml 95 97 95 97 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B24">24</xref>
###xml 142 143 142 143 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F1">1</xref>
###xml 170 172 167 169 <sub xmlns:xlink="http://www.w3.org/1999/xlink">3 </sub>
###xml 409 411 397 399 <sub xmlns:xlink="http://www.w3.org/1999/xlink">3 </sub>
###xml 517 519 499 501 <sub xmlns:xlink="http://www.w3.org/1999/xlink">3 </sub>
###xml 571 573 550 552 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F2">2a</xref>
###xml 797 799 770 772 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1 </sub>
###xml 806 808 776 778 <sub xmlns:xlink="http://www.w3.org/1999/xlink">3 </sub>
###xml 887 889 854 856 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F2">2b</xref>
###xml 905 907 869 871 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1 </sub>
###xml 1024 1026 982 984 <sub xmlns:xlink="http://www.w3.org/1999/xlink">3 </sub>
###xml 1115 1117 1067 1069 <sub xmlns:xlink="http://www.w3.org/1999/xlink">3 </sub>
Integrins regulate growth factor signaling in part via formation of integrin:RTK complexes [23,24]. Based on our findings presented in Figure 1, we hypothesized that beta3 integrins interact physically with cell surface TbetaRs. In testing this hypothesis, NMuMG cells were stimulated with TGF-beta for various periods of time, whereupon whole cell extracts were prepared and immunoprecipitated with anti-beta3 integrin antibodies. Probing the resulting immunocomplexes with anti-TbetaR-II antibodies showed that beta3 integrin did indeed interact with TbetaR-II (Figure 2a), and that EMT was necessary to induce this event. In addition, detergent-solubilized whole cell extracts prepared from control and TGF-beta stimulated NMuMG cells were immunoprecipitated with antibodies against either beta1 or beta3 integrins, and the resulting immunocomplexes were probed for TbetaR-II. Figure 2b shows that beta1 integrins interacted constitutively with TbetaR-II, whereas EMT was again required to promote the association of beta3 integrin with TbetaR-II. Collectively, these findings indicate that the formation of beta3 integrin:TbetaR-II complexes is an EMT-specific phenomena that may play an important role in regulating TGF-beta stimulation of EMT in NMuMG cells.
###end p 45
###begin title 46
###xml 4 6 1 3 <sub xmlns:xlink="http://www.w3.org/1999/xlink">3 </sub>
beta3 Integrin overexpression in NMuMG cells
###end title 46
###begin p 47
###xml 35 37 32 34 <sub xmlns:xlink="http://www.w3.org/1999/xlink">3 </sub>
###xml 162 164 153 155 <sub xmlns:xlink="http://www.w3.org/1999/xlink">3 </sub>
###xml 211 213 199 201 <sub xmlns:xlink="http://www.w3.org/1999/xlink">3 </sub>
###xml 223 225 211 213 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B34">34</xref>
###xml 257 259 242 244 <sub xmlns:xlink="http://www.w3.org/1999/xlink">3 </sub>
###xml 441 443 426 428 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B49">49</xref>
###xml 444 446 429 431 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B50">50</xref>
###xml 465 467 447 449 <sub xmlns:xlink="http://www.w3.org/1999/xlink">3 </sub>
###xml 576 578 555 557 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1 </sub>
###xml 600 602 579 581 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F3">3a</xref>
###xml 705 707 677 679 <sub xmlns:xlink="http://www.w3.org/1999/xlink">v </sub>
###xml 725 726 697 698 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F1">1</xref>
###xml 731 733 703 705 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F3">3a</xref>
###xml 758 760 727 729 <sub xmlns:xlink="http://www.w3.org/1999/xlink">3 </sub>
###xml 833 835 798 800 <sub xmlns:xlink="http://www.w3.org/1999/xlink">v </sub>
###xml 878 880 843 845 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F3">3a</xref>
###xml 892 894 854 856 <sub xmlns:xlink="http://www.w3.org/1999/xlink">3 </sub>
###xml 1043 1045 1002 1004 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F3">3a</xref>
###xml 1067 1069 1023 1025 <sub xmlns:xlink="http://www.w3.org/1999/xlink">3 </sub>
###xml 1280 1282 1236 1238 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B51">51</xref>
###xml 1354 1356 1307 1309 <sub xmlns:xlink="http://www.w3.org/1999/xlink">3 </sub>
###xml 1378 1380 1327 1329 <sub xmlns:xlink="http://www.w3.org/1999/xlink">v </sub>
To further explore the role of beta3 integrin in regulating MEC function and TGF-beta biology, we used bi-cistronic retroviral transduction to stably express beta3 integrin or its inactive counterpart D119A-beta3 integrin [34] in NMuMG cells. The D119A-beta3 integrin contains a point mutation in the conserved RGD integrin binding motif and therefore fails to bind RGD-containing ligands, such as fibronectin, vitronectin, and osteopontin [49,50]. Recombinant beta3 integrin expression in NMuMG cells was confirmed by immunoblotting whole cell extracts from basal or TGF-beta1 treated cells (Figure 3a). As observed previously, TGF-beta stimulation of EMT in NMuMG cells induced their expression of alphav integrin (Figures 1 and 3a). Interestingly, WT beta3 integrin expression induced a dramatic compensatory upregulation of alphav integrin expression in NMuMG cells (Figure 3a). This beta3 integrin response, which was independent of TGF-beta administration, was mimicked moderately by expression of its inactive D119A counterpart (Figure 3a). Although D119A beta3 integrin is considered to be functionally inactive, its heterologous expression in cells can elicit partial biologic activity in part through its ability to bind non-RGD-containing ligands, such as plasminogen [51]. Thus, these findings suggest that signals arising from activated beta3 integrins induce alphav integrin expression in MECs.
###end p 47
###begin p 48
###xml 32 34 29 31 <sub xmlns:xlink="http://www.w3.org/1999/xlink">3 </sub>
###xml 114 116 108 110 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1 </sub>
###xml 179 181 170 172 <sub xmlns:xlink="http://www.w3.org/1999/xlink">3 </sub>
###xml 320 322 308 310 <sub xmlns:xlink="http://www.w3.org/1999/xlink">3 </sub>
###xml 361 363 349 351 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F3">3b</xref>
###xml 389 391 374 376 <sub xmlns:xlink="http://www.w3.org/1999/xlink">3 </sub>
###xml 472 474 453 455 <sub xmlns:xlink="http://www.w3.org/1999/xlink">v </sub>
###xml 549 551 526 528 <sub xmlns:xlink="http://www.w3.org/1999/xlink">v </sub>
###xml 637 639 611 613 <sub xmlns:xlink="http://www.w3.org/1999/xlink">3 </sub>
###xml 656 658 630 632 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F3">3b</xref>
###xml 169 174 <span type="species:ncbi:9606">human</span>
###xml 461 466 <span type="species:ncbi:10090">mouse</span>
To confirm that recombinant beta3 integrins were expressed on the cell surface of NMuMG cells, control or TGF-beta1 treated cells were incubated with PE-conjugated anti-human beta3 integrin antibodies, and subsequently analyzed by FACS analysis. As expected, retrovirally infected NMuMG cells expressed WT and D119A beta3 integrins on their cell surfaces (Fig. 3b, left). In addition, beta3 integrin expressing cells were also incubated with PE-conjugated anti-mouse alphav integrin antibodies, which confirmed the compensatory upregulation of alphav integrins and showed their ability to form functional complexes with cell surface beta3 integrin (Figure 3b, right).
###end p 48
###begin p 49
###xml 27 29 24 26 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1 </sub>
###xml 109 111 103 105 <sub xmlns:xlink="http://www.w3.org/1999/xlink">3 </sub>
###xml 196 198 187 189 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F3">3c</xref>
###xml 217 219 205 207 <sub xmlns:xlink="http://www.w3.org/1999/xlink">3 </sub>
###xml 345 347 327 329 <sub xmlns:xlink="http://www.w3.org/1999/xlink">3 </sub>
###xml 395 397 374 376 <sub xmlns:xlink="http://www.w3.org/1999/xlink">3 </sub>
###xml 496 498 472 474 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F3">3c</xref>
###xml 580 582 547 549 <sub xmlns:xlink="http://www.w3.org/1999/xlink">3 </sub>
###xml 630 632 595 597 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n </italic>
###xml 663 665 628 630 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 729 731 691 693 <sub xmlns:xlink="http://www.w3.org/1999/xlink">3 </sub>
###xml 756 758 716 718 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n </italic>
###xml 777 779 734 736 <sub xmlns:xlink="http://www.w3.org/1999/xlink">3 </sub>
###xml 804 806 759 761 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n </italic>
###xml 1056 1058 1005 1007 <sub xmlns:xlink="http://www.w3.org/1999/xlink">3 </sub>
Finally, iodinated TGF-beta1 radioligand binding and cross-linking assays were performed to confirm that beta3 integrins did indeed interact with TbetaR-II at the cell surface. As shown in Figure 3c, WT and D119A beta3 integrins both interacted with TbetaR-II at the cell surface, indicating that formation of this complex is independent of beta3 integrin activation. Quite surprisingly, WT beta3 integrin expression, but not that of D119A, increased cell surface expression of TbetaR-II (Figure 3c). Indeed, the ratio of TbetaR-II:TbetaR-I detected at the cell surface in WT beta3 integrin expressing NMuMG cells (1.31 +/- 0.14; n = 4) was significantly higher (P = 0.009, Student's t-test) than those observed in their GFP beta3 integrin (0.76 +/- 0.05; n = 4) and D119A beta3 integrin (0.72 +/- 0.31; n = 4) expressing counterparts. Interestingly, semiquantitative real-time PCR analyses failed to detect differences in TbetaR-II transcript expression between these individual NMuMG cell lines (data not shown), suggesting that signals arising from beta3 integrins alter TbetaR-II translocation to and/or internalization from the cell surface of MECs.
###end p 49
###begin p 50
###xml 72 74 69 71 <sub xmlns:xlink="http://www.w3.org/1999/xlink">3 </sub>
###xml 186 188 179 181 <sub xmlns:xlink="http://www.w3.org/1999/xlink">v </sub>
###xml 344 345 334 335 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F1">1</xref>
###xml 350 351 340 341 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F2">2</xref>
###xml 399 401 386 388 <sub xmlns:xlink="http://www.w3.org/1999/xlink">3 </sub>
###xml 506 508 487 489 <sub xmlns:xlink="http://www.w3.org/1999/xlink">3 </sub>
###xml 62 67 <span type="species:ncbi:9606">human</span>
Collectively, these findings show that retrovirally expressed human beta3 integrins were translocated to the cell surface of NMuMG cells, where they formed active heterodimers with alphav integrin, and more importantly they interacted physically with TbetaR-II at the plasma membrane. In addition, these findings and those presented in Figures 1 and 2 illustrate a unique and essential role for beta3 integrin in promoting EMT, particularly that mediated by TGF-beta, and suggest that the formation of beta3 integrin:TbetaR-II complexes may alter the response of MECs to TGF-beta by regulating its intracellular signaling systems.
###end p 50
###begin title 51
###xml 4 6 1 3 <sub xmlns:xlink="http://www.w3.org/1999/xlink">3 </sub>
beta3 Integrin expression enhances MAPK activation by TGF-beta in NMuMG cells
###end title 51
###begin p 52
###xml 80 82 80 82 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B23">23</xref>
###xml 83 85 83 85 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B52">52</xref>
###xml 196 197 193 194 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B2">2</xref>
###xml 198 200 195 197 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B15">15</xref>
###xml 201 203 198 200 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B16">16</xref>
###xml 242 244 236 238 <sub xmlns:xlink="http://www.w3.org/1999/xlink">3 </sub>
###xml 357 359 345 347 <sub xmlns:xlink="http://www.w3.org/1999/xlink">3 </sub>
###xml 459 461 444 446 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F4">4a</xref>
###xml 603 605 585 587 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F4">4a</xref>
###xml 689 691 671 673 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B23">23</xref>
###xml 810 812 789 791 <sub xmlns:xlink="http://www.w3.org/1999/xlink">3 </sub>
###xml 921 923 894 896 <sub xmlns:xlink="http://www.w3.org/1999/xlink">3 </sub>
###xml 1003 1004 973 974 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1</sub>
###xml 1037 1039 1007 1009 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F4">4b</xref>
###xml 1055 1057 1022 1024 <sub xmlns:xlink="http://www.w3.org/1999/xlink">3 </sub>
###xml 1239 1241 1200 1202 <sub xmlns:xlink="http://www.w3.org/1999/xlink">3 </sub>
The coupling of integrins to RTKs often is associated with activation of MAPKs [23,52]. This is noteworthy because the activation of MAPKs is essential for the ability of TGF-beta to promote EMT [2,15,16]. We therefore determined whether beta3 integrin expression altered the ability of TGF-beta to activate MAPKs in NMuMG cells. Although expression of beta3 integrin in NMuMG cells had negligible effects on TGF-beta stimulated Smad2 phosphorylation (Figure 4a) and nuclear translocation (data not shown), its expression significantly enhanced the activation of ERK1/2 and p38 MAPK by TGF-beta (Figure 4a). Integrin expression can elicit dramatic changes in cell adhesion and morphology [23], potentially resulting in global alterations in intracellular signaling systems. To determine the specificity of beta3 integrin expression to TGF-beta signaling, we monitored the activation status of p38 MAPK in control and beta3 integrin expressing NMuMG cells before and after their stimulation with TGF-beta1, prolactin, PMA, or EGF. Figure 4b shows that beta3 integrin expression selectively regulated the coupling of TGF-beta, but not that of prolactin, PMA, or EGF, to p38 MAPK activation in NMuMG cells. Thus, these findings implicate beta3 integrins as unique mediators of TGF-beta signaling in MECs.
###end p 52
###begin title 53
###xml 4 6 1 3 <sub xmlns:xlink="http://www.w3.org/1999/xlink">3 </sub>
beta3 Integrin expression blocked TGF-beta stimulated growth arrest but enhanced TGF-beta mediated invasion and EMT in NMuMG cells
###end title 53
###begin p 54
###xml 30 32 27 29 <sub xmlns:xlink="http://www.w3.org/1999/xlink">3 </sub>
###xml 122 124 113 115 <sub xmlns:xlink="http://www.w3.org/1999/xlink">3 </sub>
###xml 262 264 247 249 <sub xmlns:xlink="http://www.w3.org/1999/xlink">3 </sub>
###xml 406 408 388 390 <sub xmlns:xlink="http://www.w3.org/1999/xlink">3 </sub>
###xml 492 494 472 474 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n </italic>
###xml 499 501 479 481 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 546 548 523 525 <sub xmlns:xlink="http://www.w3.org/1999/xlink">3 </sub>
###xml 630 632 605 607 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n </italic>
###xml 637 639 612 614 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 723 725 695 697 <sub xmlns:xlink="http://www.w3.org/1999/xlink">3 </sub>
###xml 887 889 856 858 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F5">5a</xref>
###xml 912 914 878 880 <sub xmlns:xlink="http://www.w3.org/1999/xlink">3 </sub>
###xml 1027 1029 990 992 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F5">5a</xref>
###xml 1052 1054 1012 1014 <sub xmlns:xlink="http://www.w3.org/1999/xlink">3 </sub>
Based upon the ability of beta3 integrins to enhance MAPK activation by TGF-beta, we next sought to determine whether beta3 integrins could alter the ability of TGF-beta to regulate MEC cell proliferation, invasion, and EMT. We first measured the effects of beta3 integrin expression on the rate of DNA synthesis in resting NMuMG cells. As compared with GFP expressing NMuMG cells, those expressing WT beta3 integrin exhibited significantly increased rates of DNA synthesis (by 78 +/- 0.12%; n = 3; P = 0.002), whereas those expressing D119A beta3 integrin exhibited significantly retarded rates of DNA synthesis (by 68 +/- 4.0%; n = 3; P = 0.00007). Despite the relative growth rate differences observed between these beta3 integrin expressing NMuMG cell derivatives, the response of GFP and D119A expressing NMuMG cells to TGF-beta mediated cytostasis was surprisingly similar (Figure 5a). In contrast, WT beta3 integrin expression significantly reduced the ability of TGF-beta to induce growth arrest in NMuMG cells (Figure 5a), indicating that beta3 integrin expression significantly reduces cytostasis mediated by TGF-beta, thereby circumventing its tumor suppressor function in MECs.
###end p 54
###begin p 55
###xml 31 33 28 30 <sub xmlns:xlink="http://www.w3.org/1999/xlink">3 </sub>
###xml 155 157 146 148 <sub xmlns:xlink="http://www.w3.org/1999/xlink">3 </sub>
###xml 261 263 252 254 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F5">5b</xref>
###xml 540 542 522 524 <sub xmlns:xlink="http://www.w3.org/1999/xlink">3 </sub>
###xml 629 631 608 610 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F5">5b</xref>
###xml 674 676 650 652 <sub xmlns:xlink="http://www.w3.org/1999/xlink">3 </sub>
###xml 781 783 757 759 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F5">5b</xref>
###xml 824 826 797 799 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1 </sub>
###xml 925 927 898 900 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F5">5b</xref>
###xml 991 993 964 966 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B11">11</xref>
###xml 1076 1078 1046 1048 <sub xmlns:xlink="http://www.w3.org/1999/xlink">3 </sub>
###xml 1172 1174 1139 1141 <sub xmlns:xlink="http://www.w3.org/1999/xlink">3 </sub>
###xml 1241 1243 1208 1210 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F5">5c</xref>
###xml 1305 1307 1272 1274 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F5">5c</xref>
###xml 1385 1387 1349 1351 <sub xmlns:xlink="http://www.w3.org/1999/xlink">3 </sub>
###xml 1472 1474 1430 1432 <sub xmlns:xlink="http://www.w3.org/1999/xlink">3 </sub>
We also determined whether beta3 integrins are capable of enhancing the tumor promoting functions of TGF-beta. In doing so, we compared the ability of beta3 integrin expressing NMuMG cell lines to invade through synthetic basement membranes. As shown in Figure 5b, GFP expressing NMuMG cells exhibited minimal invasion through Matrigel matrices in response to serum stimulation, a response that was enhanced insignificantly by TGF-beta treatment. Similar to its inability to alter growth regulation by TGF-beta, expression of the D119A beta3 integrin in NMuMG cells failed to affect their TGF-beta regulated invasiveness (Figure 5b). In contrast, NMuMG cells expressing beta3 integrin exhibited a trend toward increased invasiveness to serum as compared with control cells (Figure 5b); however, when stimulated with TGF-beta1 these cells exhibited significantly enhanced invasion through synthetic basement membranes (Figure 5b). Because increased invasiveness is often associated with EMT [11], we examined the morphology and actin cytoskeleton of NMuMG cells expressing beta3 integrins. Consistent with our previous results, only those NMuMG cells that expressed WT beta3 integrin acquired an elongated, fibroblast-like morphology (Figure 5c), complete with the formation of actin stress fibers (Figure 5c). Taken together, these findings suggest that although both WT and D119A beta3 integrins can form complexes with TbetaR-II at the cell surface, only functional beta3 integrins are capable of inducing EMT and invasion in NMuMG cells.
###end p 55
###begin p 56
###xml 186 188 183 185 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F5">5d</xref>
###xml 212 214 206 208 <sub xmlns:xlink="http://www.w3.org/1999/xlink">3 </sub>
###xml 361 363 349 351 <sub xmlns:xlink="http://www.w3.org/1999/xlink">3 </sub>
Lastly, we monitored changes in TGF-beta stimulated gene expression by measuring differences in luciferase expression driven by the synthetic SBE (Smad binding element) promoter. Figure 5d shows that only WT beta3 integrin expression significantly enhanced TGF-beta stimulated gene expression as compared with control cells or those expressing its inactive beta3 integrin counterpart.
###end p 56
###begin p 57
###xml 104 106 101 103 <sub xmlns:xlink="http://www.w3.org/1999/xlink">3 </sub>
###xml 300 302 285 287 <sub xmlns:xlink="http://www.w3.org/1999/xlink">3 </sub>
Collectively, these findings indicate that, unlike its nonfunctional counterparts, expression of WT beta3 integrin in MECs diminished TGF-beta mediated growth arrest, enhanced TGF-beta mediated invasion and EMT, and augmented TGF-beta mediated gene expression. Moreover, our results suggest that beta3 integrin expression translates TGF-beta from an inhibitor of MEC cell growth to a stimulator of their invasion and EMT.
###end p 57
###begin title 58
Dual receptor activation induces Src-mediated TbetaR-II tyrosine phosphorylation
###end title 58
###begin p 59
###xml 36 38 33 35 <sub xmlns:xlink="http://www.w3.org/1999/xlink">3 </sub>
###xml 101 103 89 91 <sub xmlns:xlink="http://www.w3.org/1999/xlink">3 </sub>
###xml 176 178 158 160 <sub xmlns:xlink="http://www.w3.org/1999/xlink">3 </sub>
###xml 282 284 258 260 <sub xmlns:xlink="http://www.w3.org/1999/xlink">3 </sub>
###xml 555 557 522 524 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1 </sub>
###xml 662 664 623 625 <sub xmlns:xlink="http://www.w3.org/1999/xlink">3 </sub>
###xml 731 733 692 694 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F6">6a</xref>
###xml 854 856 806 808 <sub xmlns:xlink="http://www.w3.org/1999/xlink">3 </sub>
###xml 930 932 876 878 <sub xmlns:xlink="http://www.w3.org/1999/xlink">3 </sub>
###xml 960 961 906 907 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F1">1</xref>
###xml 1008 1009 951 952 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F2">2</xref>
###xml 1118 1120 1055 1057 <sub xmlns:xlink="http://www.w3.org/1999/xlink">3 </sub>
###xml 1211 1213 1142 1144 <sub xmlns:xlink="http://www.w3.org/1999/xlink">3 </sub>
###xml 1331 1333 1262 1264 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F6">6b</xref>
###xml 1380 1382 1305 1307 <sub xmlns:xlink="http://www.w3.org/1999/xlink">3 </sub>
###xml 1405 1407 1327 1329 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1 </sub>
###xml 1497 1499 1416 1418 <sub xmlns:xlink="http://www.w3.org/1999/xlink">3 </sub>
###xml 1576 1578 1492 1494 <sub xmlns:xlink="http://www.w3.org/1999/xlink">3 </sub>
###xml 1658 1660 1568 1570 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F6">6b</xref>
###xml 1673 1675 1580 1582 <sub xmlns:xlink="http://www.w3.org/1999/xlink">3 </sub>
###xml 1827 1829 1728 1730 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B23">23</xref>
Our findings thus far show that beta3 integrin and TbetaR-II interact upon TGF-beta stimulation, beta3 integrin expression is essential for EMT stimulated by TGF-beta, and beta3 integrin expression influences the MEC response to TGF-beta. To further explore the consequences of beta3 integrin:TbetaR-II complex formation, GFP expressing NMuMG cells were incubated in the absence or presence of TGF-beta for 36 hours, and subsequently were held in suspension before re-plating onto plastic or vitronectin-coated wells in the absence or presence of TGF-beta1 for 5 min. Afterward, the phosphorylation status of TbetaR-II and its ability to form complexes with beta3 integrin were monitored by co-immunoprecipitation analyses. Figure 6a shows that following TGF-beta induced EMT, TbetaR-II was constitutively tyrosine phosphorylated and associated with beta3 integrin. Because chronic TGF-beta stimulation of NMuMG cells induces beta3 integrin expression (Figure 1) and complex formation with TbetaR-II (Figure 2), it was difficult to assess the role of TGF-beta receptor and integrin stimulation in the formation of beta3 integrin:TbetaR-II complexes in NMuMG cells. To circumvent this difficulty, resting WT beta3 integrin expressing NMuMG cells were dissociated and subsequently replated and stimulated for 5 min, as above. Figure 6b shows that TbetaR-II only interacted with beta3 integrins upon TGF-beta1 stimulation and, more importantly, that this response was enhanced significantly upon beta3 integrin adhesion. In addition, only upon dual receptor activation (i.e. beta3 integrin and TbetaRs) was TbetaR-II phosphorylated on tyrosine residues (Figure 6b). Thus, beta3 integrin regulates TGF-beta signaling by targeting TbetaR-II for tyrosine phosphorylation in a manner reminiscent of integrin actions on RTK signaling [23].
###end p 59
###begin p 60
###xml 196 198 196 198 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B22">22</xref>
###xml 383 392 380 389 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in vitro </italic>
###xml 621 623 615 617 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F6">6c</xref>
###xml 793 795 784 786 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F6">6d</xref>
###xml 840 849 828 837 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in vitro </italic>
###xml 857 859 845 847 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F6">6c</xref>
###xml 926 928 908 910 <sub xmlns:xlink="http://www.w3.org/1999/xlink">3 </sub>
Although integrins lack intrinsic protein tyrosine kinase (PTK) activity, they facilitate tyrosine phosphorylation of target proteins via their recruitment of FAK and Src PTKs to focal adhesions [22]. We therefore hypothesized that FAK or Src are potential PTKs responsible for phosphorylating TbetaR-II on tyrosine residues in NMuMG cells. We tested this hypothesis by utilizing an in vitro PTK assay that measured the ability of purified, active FAK or Src to phosphorylate GST fusion proteins containing catalytically active or inactive (i.e. K277R) versions of the cytoplasmic domain of TbetaR-II. As shown in Figure 6c, Src phosphorylated the cytoplasmic domain of TbetaR-II on tyrosine residues. Although active and capable of undergoing autophosphorylation on tyrosine residues (Figure 6d), FAK was unable to phosphorylate TbetaR-II in vitro (Figure 6c), suggesting that Src phosphorylates TbetaR-II in response to beta3 integrin expression.
###end p 60
###begin p 61
###xml 280 282 274 276 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B53">53</xref>
###xml 614 622 596 604 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in vitro</italic>
###xml 724 726 703 705 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F7">7a</xref>
###xml 799 801 778 780 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F7">7a</xref>
###xml 944 946 920 922 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F7">7a</xref>
###xml 1092 1094 1062 1064 <sub xmlns:xlink="http://www.w3.org/1999/xlink">3 </sub>
###xml 1238 1240 1202 1204 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F7">7b</xref>
###xml 1337 1339 1295 1297 <sub xmlns:xlink="http://www.w3.org/1999/xlink">3 </sub>
###xml 1448 1450 1403 1405 <sub xmlns:xlink="http://www.w3.org/1999/xlink">3 </sub>
###xml 1639 1641 1591 1593 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F7">7c</xref>
###xml 1693 1695 1642 1644 <sub xmlns:xlink="http://www.w3.org/1999/xlink">3 </sub>
To further examine the functional link between Src and TbetaR-II, we attempted to inhibit Src activity or function in NMuMG cells and subsequently monitor the consequences of these manipulations on TbetaR-II tyrosine phosphorylation. Recent work conducted by Maeda and coworkers [53] showed that the broad spectrum protein kinase inhibitor PP1 antagonizes TGF-beta signaling by inhibiting TbetaR-I and TbetaR-II protein kinase activity. As such, we monitored the effects of two Src inhibitors, PP2 and SU6656, on the ability of immunoprecipitated TGF-beta receptor complexes to phosphorylate recombinant GST-Smad3 in vitro. As expected, TGF-beta stimulation greatly enhanced the phosphorylation of recombinant Smad3 (Figure 7a), a reaction that was reduced markedly by SU6656 administration (Figure 7a). In contrast, PP2 treatment failed to inhibit TbetaR activity and instead appeared to elicit agonist independent receptor activation (Figure 7a). Based on its inactivity against TbetaRs, PP2 appeared to be a suitable pharmacological agent to inhibit Src activity in MECs. Accordingly, beta3 integrin-expressing NMuMG cells treated with PP2 abrogated the tyrosine phosphorylation of TbetaR-II in TGF-beta stimulated NMuMG cells (Figure 7b), indicating that Src activity does indeed mediate tyrosine phosphorylation of TbetaR-II in beta3 integrin expressing NMuMG cells. Along these lines, transient expression of constitutively active Src in beta3 integrin expressing NMuMG cells resulted in significantly elevated tyrosine phosphorylation of TbetaR-II, an event that was not recapitulated by expression of dominant negative Src (Figure 7c). Taken together, these findings indicate that beta3 integrin-mediated recruitment of Src facilitates the tyrosine phosphorylation of TbetaR-II in MECs, and that this phosphorylation event may act to enhance their proliferation, invasion, and EMT by augmenting the ability of TGF-beta to activate MAPKs.
###end p 61
###begin title 62
###xml 26 28 23 25 <sub xmlns:xlink="http://www.w3.org/1999/xlink">3 </sub>
Src inhibition blocks beta3 integrin and TGF-beta mediated MAPK activation, EMT, and invasion in NMuMG cells
###end title 62
###begin p 63
###xml 277 279 268 270 <sub xmlns:xlink="http://www.w3.org/1999/xlink">3 </sub>
###xml 372 374 360 362 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1 </sub>
###xml 394 396 382 384 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F8">8a</xref>
###xml 536 538 521 523 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F8">8a</xref>
###xml 645 647 627 629 <sub xmlns:xlink="http://www.w3.org/1999/xlink">3 </sub>
###xml 757 759 736 738 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F8">8b</xref>
###xml 1031 1033 1004 1006 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F8">8c</xref>
###xml 1177 1179 1147 1149 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F8">8c</xref>
We next explored the functional importance of Src in regulating various MEC responses to TGF-beta. To do so, NMuMG cells were pretreated with either PP2 or its inactive counterpart PP3 and subsequently stimulated with TGF-beta to activate ERK1/2 and p38 MAPK. As expected, beta3 integrin expression significantly increased ERK1/2 and p38 MAPK activation following TGF-beta1 stimulation (Figure 8a). This response to TGF-beta was unaffected by PP3 administration, but it was reduced significantly by PP2 treatment of NMuMG cells (Figure 8a). More importantly, PP2 administration completely reverted the EMT phenotype induced by expression of beta3 integrin in NMuMG cells, and nearly abolished the ability of TGF-beta to stimulate EMT in NMuMG cells (Figure 8b). We also engineered NMuMG cells to stably express dominant negative Src and subsequently measured its effect on the ability of TGF-beta to induce EMT and invasion in MECs. As expected, GFP expressing NMuMG cells readily underwent EMT when stimulated by TGF-beta (Figure 8c). In stark contrast, NMuMG cells expressing dominant negative Src were stunted in their ability to undergo EMT in response to TGF-beta (Figure 8c), and instead formed small, disorganized stress fibers that contrasted sharply with those produced in their GFP expressing counterparts.
###end p 63
###begin p 64
###xml 91 93 91 93 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B54">54</xref>
###xml 415 417 412 414 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F8">8d</xref>
###xml 498 500 492 494 <sub xmlns:xlink="http://www.w3.org/1999/xlink">3 </sub>
###xml 599 601 590 592 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F8">8d</xref>
###xml 665 667 653 655 <sub xmlns:xlink="http://www.w3.org/1999/xlink">3 </sub>
###xml 787 789 772 774 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F8">8d</xref>
###xml 819 821 801 803 <sub xmlns:xlink="http://www.w3.org/1999/xlink">3 </sub>
Proper organization of cell polarity is essential for cancer cell invasion and metastasis [54]. Based on the aberrant EMT response observed in dominant negative Src expressing NMuMG cells, we suspected that their invasion through synthetic basement membranes would also be impaired. Accordingly, dominant negative Src expression significantly inhibited the ability of TGF-beta to induce NMuMG cell invasion (Figure 8d). Interestingly, singular expression of either constitutively active Src or beta3 integrin in NMuMG cells significantly enhanced tonic and TGF-beta stimulated cell invasion (Figure 8d). More importantly, introducing dominant negative Src into beta3 integrin expressing NMuMG cells completely abolished the ability of TGF-beta to stimulate cell invasion in MECs (Figure 8d). Thus, activity of both beta3 integrin and Src is necessary for MEC invasion stimulated by TGF-beta.
###end p 64
###begin p 65
###xml 303 305 297 299 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F8">8e</xref>
###xml 480 482 468 470 <sub xmlns:xlink="http://www.w3.org/1999/xlink">3 </sub>
###xml 499 501 487 489 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F1">1c</xref>
Finally, the findings above suggest that Src may play an essential role in facilitating EMT stimulated by TGF-beta. We tested this hypothesis by transiently transfecting NMuMG cells with siRNAs directed against Src and subsequently monitored their ability to undergo EMT in response to TGF-beta. Figure 8e shows that Src deficiency did indeed abolish the ability of TGF-beta to stimulate EMT in NMuMG cells, a response reminiscent of that observed in NMuMG cells deficient in beta3 integrin (Figure 1c). Collectively, these findings indicate that Src expression and activity are essential for the ability of TGF-beta to stimulate MAPKs, and to induce EMT and cell invasion in MECs.
###end p 65
###begin title 66
###xml 4 6 1 3 <sub xmlns:xlink="http://www.w3.org/1999/xlink">3 </sub>
###xml 49 54 <span type="species:ncbi:9606">human</span>
beta3 Integrin expression increases in malignant human MECs and regulates invasion stimulated by TGF-beta
###end title 66
###begin p 67
###xml 76 78 73 75 <sub xmlns:xlink="http://www.w3.org/1999/xlink">3 </sub>
###xml 216 218 210 212 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B26">26</xref>
###xml 219 221 213 215 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B27">27</xref>
###xml 588 590 582 584 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B55">55</xref>
###xml 713 714 704 705 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B9">9</xref>
###xml 388 393 <span type="species:ncbi:9606">human</span>
Our findings have thus far solely investigated the relationship between beta3 integrins and TGF-beta in normal MECs. It should be noted that cells undergoing neoplastic transformation, including those of the breast [26,27], exhibit altered integrin expression profiles during tumorigenesis, suggesting that integrins could play a key role in the acquisition of neoplastic phenotypes. The human MCF10A system consists of a series MEC cell lines that share a common ancestry and represent distinct stages of breast cancer development, ranging from normal to highly invasive and metastatic [55]; they also represent a model system for studying the conversion of TGF-beta from a tumor suppressor to a tumor promoter [9].
###end p 67
###begin p 68
###xml 88 90 85 87 <sub xmlns:xlink="http://www.w3.org/1999/xlink">3 </sub>
###xml 240 242 234 236 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F9">9a</xref>
###xml 269 271 260 262 <sub xmlns:xlink="http://www.w3.org/1999/xlink">3 </sub>
###xml 438 440 426 428 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F9">9b</xref>
###xml 617 619 599 601 <sub xmlns:xlink="http://www.w3.org/1999/xlink">3 </sub>
###xml 647 649 629 631 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F9">9c</xref>
###xml 675 677 654 656 <sub xmlns:xlink="http://www.w3.org/1999/xlink">3 </sub>
###xml 788 790 764 766 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F9">9c</xref>
###xml 866 868 839 841 <sub xmlns:xlink="http://www.w3.org/1999/xlink">3 </sub>
###xml 921 923 891 893 <sub xmlns:xlink="http://www.w3.org/1999/xlink">3 </sub>
Interestingly, breast cancer progression was associated with elevated expression of beta3 integrin and its effector, FAK, which correlated with the conversion of TGF-beta from a suppressor to a promoter of breast cancer progression (Figure 9a). Moreover, exogenous beta3 integrin expression in normal, poorly invasive MCF10A cells significantly enhanced their invasion through synthetic basement membranes in response to TGF-beta (Figure 9b). In contrast, the malignant, metastatic MCF10CA1a cells readily invaded Matrigel matrices when stimulated with TGF-beta, a response that was augmented significantly by WT beta3 integrin expression (Figure 9c). Importantly, D119A beta3 integrin expression completely abolished the ability of TGF-beta to stimulate MCF10ACA1a cell invasion (Figure 9c). Collectively, our findings suggest that mammary tumorigenesis alters beta3 integrin expression in neoplastic MECs, and that beta3 integrins may play a crucial role in translating TGF-beta from a suppressor to a promoter of breast cancer growth and invasion.
###end p 68
###begin title 69
Discussion
###end title 69
###begin p 70
###xml 166 168 166 168 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B11">11</xref>
###xml 169 171 169 171 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B48">48</xref>
###xml 382 384 376 378 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B56">56</xref>
The process of EMT recently has been subject to intense research investigation because of its importance in mediating cancer cell motility, invasion, and metastasis [11,48]. TGF-beta is a major regulator of both developmental and pathological EMT, particularly that in diseased MECs, which frequently exhibit decreased cytostasis and increased invasiveness in response to TGF-beta [56]. Unfortunately, the molecular mechanisms underlying the conversion of TGF-beta from an inhibitor of MEC proliferation to an inducer of their EMT are poorly understood. Because cell microenvironmental changes regulate cancer development and progression, including the acquisition of EMT, and because integrins and TGF-beta are major regulators of cell microenvironments, we hypothesized that differential integrin expression induced by TGF-beta would contribute to its regulation of MEC proliferation and EMT.
###end p 70
###begin p 71
###xml 34 36 31 33 <sub xmlns:xlink="http://www.w3.org/1999/xlink">3 </sub>
###xml 185 187 176 178 <sub xmlns:xlink="http://www.w3.org/1999/xlink">3 </sub>
###xml 265 267 253 255 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F1">1c</xref>
###xml 304 306 289 291 <sub xmlns:xlink="http://www.w3.org/1999/xlink">3 </sub>
###xml 414 415 393 394 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F2">2</xref>
###xml 515 516 491 492 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F5">5</xref>
###xml 541 543 514 516 <sub xmlns:xlink="http://www.w3.org/1999/xlink">3 </sub>
###xml 620 621 590 591 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F6">6</xref>
###xml 708 709 675 676 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F8">8</xref>
###xml 760 761 727 728 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F8">8</xref>
###xml 831 833 795 797 <sub xmlns:xlink="http://www.w3.org/1999/xlink">3 </sub>
###xml 948 950 909 911 <sub xmlns:xlink="http://www.w3.org/1999/xlink">3 </sub>
###xml 1039 1040 997 998 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F9">9</xref>
###xml 1117 1119 1072 1074 <sub xmlns:xlink="http://www.w3.org/1999/xlink">3 </sub>
To this end, we now show that beta3 integrin expression alters the response of MECs to TGF-beta, particularly its ability to regulate cell proliferation, invasion, and EMT. Indeed, beta3 integrin expression appears essential for TGF-beta stimulation of EMT (Figure 1c). Moreover, we demonstrate that beta3 integrin directly couples to the TGF-beta signaling system by interacting physically with TbetaR-II (Figure 2), resulting in enhanced MEC proliferation, invasion, and EMT when stimulated with TGF-beta (Figure 5). More importantly, beta3 integrin promotes Src mediated tyrosine phosphorylation of TbetaR-II (Figure 6), which we show to be essential for the ability of TGF-beta to activate MAPKs (Figure 8) and, consequently, to induce EMT in MECs (Figure 8). More importantly, we show for the first time that induction of beta3 integrin expression during mammary tumorigenesis correlates with metastasis development, and that antagonizing beta3 integrin signaling abolishes TGF-beta stimulation of breast cancer cell invasion (Figure 9). Collectively, we identified a potentially important mechanism whereby beta3 integrin expression selectively facilitates TGF-beta stimulation of MEC invasion and EMT.
###end p 71
###begin p 72
###xml 267 269 267 269 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B52">52</xref>
###xml 442 444 442 444 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B24">24</xref>
###xml 482 484 482 484 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B42">42</xref>
###xml 503 504 499 500 <sub xmlns:xlink="http://www.w3.org/1999/xlink">v</sub>
###xml 508 510 501 503 <sub xmlns:xlink="http://www.w3.org/1999/xlink">3 </sub>
###xml 683 684 666 667 <sub xmlns:xlink="http://www.w3.org/1999/xlink">v</sub>
###xml 688 690 668 670 <sub xmlns:xlink="http://www.w3.org/1999/xlink">3 </sub>
###xml 790 792 764 766 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B42">42</xref>
###xml 839 841 810 812 <sub xmlns:xlink="http://www.w3.org/1999/xlink">3 </sub>
###xml 1003 1005 965 967 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B57">57</xref>
###xml 1120 1122 1079 1081 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B58">58</xref>
###xml 1387 1389 1337 1339 <sub xmlns:xlink="http://www.w3.org/1999/xlink">3 </sub>
###xml 1423 1425 1370 1372 <sub xmlns:xlink="http://www.w3.org/1999/xlink">3 </sub>
###xml 1498 1500 1439 1441 <sub xmlns:xlink="http://www.w3.org/1999/xlink">3 </sub>
The joint activation of integrin and RTK signaling systems is essential for the positional control of cells. More importantly, cell attachment to the ECM also determines the nature and context of how cells interpret and respond to cytokine and growth factor binding [52]. For instance, the ability of EGF and platelet-derived growth factor receptors to stimulate fibroblast migration requires RTK receptor association with integrins and FAK [24]. Similarly, Scaffidi and coworkers [42] showed that alphavbeta3 integrin bound TbetaR-II in lung fibroblasts, thereby enhancing fibroblast proliferation stimulated by TGF-beta. Those authors further speculated that the formation of alphavbeta3 integrin:TbetaR-II complexes may exacerbate TGF-beta mediated wound healing and fibrotic reactions [42], processes reminiscent of the ability of beta3 integrin:TbetaR-II complexes to drive TGF-beta stimulation of EMT in MECs. Most recently, the adapter protein Dab2, which mediates Smad2/3 activation by TbetaRs [57], was shown to participate in TGF-beta stimulated EMT by interacting with integrins and preventing MEC apoptosis [58]. These findings, together with those presented herein, indicate an important and underappreciated role for integrins in regulating cellular response to TGF-beta. Future studies in MECs must determine the relationship between TGF-beta stimulated expression of beta3 integrin and Dab2, as well as beta3 integrin stimulated TbetaR-II expression in MECs; whether Dab2 links beta3 integrin to TbetaR-II during EMT; and the ability of additional integrins to influence, either positively or negatively, MEC response to TGF-beta.
###end p 72
###begin p 73
###xml 73 75 70 72 <sub xmlns:xlink="http://www.w3.org/1999/xlink">3 </sub>
###xml 428 429 413 414 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B8">8</xref>
###xml 430 432 415 417 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B13">13</xref>
###xml 433 435 418 420 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B59">59</xref>
###xml 552 554 534 536 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B60">60</xref>
###xml 660 662 639 641 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B61">61</xref>
###xml 1041 1043 1011 1013 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B61">61</xref>
###xml 1384 1393 1348 1357 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in vitro </italic>
A particularly novel finding of our study was the demonstration that beta3 integrin induced TbetaR-II tyrosine phosphorylation via Src kinase. Indeed, we show for the first time that Src activity mediates tyrosine phosphorylation of TbetaR-II in MECs, leading to TGF-beta mediated MAPK activation, and to MEC invasion and EMT. Previous studies established that TbetaR-II is phosphorylated predominantly on Ser and Thr residues [8,13,59], which, depending on the site of phosphorylation, either augments or attenuates TbetaR-II protein kinase activity [60]. However, tyrosine phosphorylation of TbetaR-II is not without precedent. Indeed, Lawler and coworkers [61] showed that TbetaR-II is a dual-specificity protein kinase that autophosphorylates not only on Ser/Thr residues but also on tyrosine 259, 336, and 424. Moreover, although Phe substitution at these positions significantly reduced TbetaR-II protein kinase activity, these mutations had little affect on the ability of TGF-beta to induce gene expression in lung epithelial cells [61], and as such the role of tyrosines 259, 336, and 424 in mediating TGF-beta action remain to be clarified. We too have converted tyrosines 259, 336, and 424 to phenylalanine in all possible combinations (i.e. single, double, and triple mutations), all of which failed to alter Src mediated tyrosine phosphorylation of GST-TbetaR-II (K277R) in vitro (Galliher AJ, Schiemann WP, unpublished data). Sequence analysis of the cytoplasmic domain of TbetaR-II revealed two possible Src phosphorylation consensus motifs at tyrosines 284 and 470. These two sites were individually mutated to phenylalanines, and preliminary data suggest that Src phosphorylates TbetaR-II at tyrosine 284 (Galliher AJ, Schiemann WP, unpublished data). Further analysis of this site in mediating TGF-beta stimulation of EMT in MECs is currently under investigation.
###end p 73
###begin p 74
###xml 50 51 50 51 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B5">5</xref>
###xml 67 68 67 68 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B2">2</xref>
###xml 69 71 69 71 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B32">32</xref>
###xml 408 410 396 398 <sub xmlns:xlink="http://www.w3.org/1999/xlink">3 </sub>
###xml 616 618 598 600 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B62">62</xref>
###xml 619 621 601 603 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B64">64</xref>
###xml 699 701 678 680 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B65">65</xref>
###xml 924 926 893 895 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B66">66</xref>
Activation of MAPKs, particularly that of ERK1/2 [5] and p38 MAPK [2,32], are necessary for TGF-beta to stimulate EMT. We also found that TGF-beta stimulation of ERK1/2 and p38 MAPK are necessary for induction of EMT in MECs. More importantly, we show for the first time that Src activity is essential for activation of MAPKs by TGF-beta and for its stimulation of EMT. Indeed, our results indicate that beta3 integrin expression and Src activity are sufficient in overcoming TGF-beta mediated cytostasis in MECs. Src activity also has been associated with protecting hepatocytes from apoptosis induced by TGF-beta [62-64] and with the ability of TGF-beta to stimulate ovarian cancer cell invasion [65]. More recently, TGF-beta treatment of MECs was shown to induce their expression of RPTPkappa, a protein tyrosine phosphatase that activates Src and mediates the antiproliferative and the promigratory effects of TGF-beta [66]. These findings, together with those presented herein, implicate Src as an important player operant in dictating the MEC response to TGF-beta; they also suggest that Src inhibition, similar to integrin interdiction, may one day be used to enhance the tumor suppressing activities of TGF-beta in breast cancer cells.
###end p 74
###begin p 75
###xml 138 140 138 140 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B67">67</xref>
###xml 366 368 360 362 <sub xmlns:xlink="http://www.w3.org/1999/xlink">3 </sub>
###xml 509 511 494 496 <sub xmlns:xlink="http://www.w3.org/1999/xlink">3 </sub>
###xml 670 672 649 651 <sub xmlns:xlink="http://www.w3.org/1999/xlink">3 </sub>
###xml 1105 1107 1075 1077 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B37">37</xref>
###xml 1108 1110 1078 1080 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B68">68</xref>
Finally, based on the fact that phosphotyrosine residues often create binding motifs that couple receptors to various signaling pathways [67], including the MAPK cascade, it is tempting to speculate that Src-mediated tyrosine phosphorylation of TbetaR-II functions similarly as a receptor docking site to recruit SH2 and/or PTB containing signaling molecules to beta3 integrin:TbetaR-II complexes. If correct, then such a mechanism could account for the augmented ability of TGF-beta to activate MAPKs in beta3 integrin expressing MECs, and for the shift in MAPK and Smad2/3 signaling that favored EMT over cytostasis in response to TGF-beta. Indeed, the ability of beta3 integrin to increase Smad2/3 transcriptional activity without altering Smad2/3 phosphorylation suggests that other integrin or MAPK stimulated nuclear factors converge on TGF-beta targeted promoters and synergize with Smad2/3 in coordinating gene expression regulated by TGF-beta. This notion is wholly consistent with previous work demonstrating the ability of Smad2/3 to synergize with activated TbetaR complexes in mediating EMT [37,68].
###end p 75
###begin title 76
Conclusion
###end title 76
###begin p 77
###xml 72 74 69 71 <sub xmlns:xlink="http://www.w3.org/1999/xlink">3 </sub>
###xml 255 257 246 248 <sub xmlns:xlink="http://www.w3.org/1999/xlink">3 </sub>
In summary, we present evidence that the differential expression of beta3 integrin induced by TGF-beta functions to convert this cytokine from an inhibitor of MEC proliferation to a stimulator of their EMT and invasion. More importantly, we show that beta3 integrin regulates TGF-beta signaling by interacting physically with TbetaR-II and stimulating its phosphorylation on tyrosine residues by Src. The net effect of these events results in enhanced TGF-beta stimulation of MAPKs and, consequently, induction of EMT and invasion in MECs. Indeed, our findings suggest that integrin interdiction may prevent tumor development and progression by maintaining, reinforcing, or re-establishing the tumor suppressing activities of TGF-beta.
###end p 77
###begin title 78
Abbreviations
###end title 78
###begin p 79
###xml 295 296 295 296 <italic xmlns:xlink="http://www.w3.org/1999/xlink">S</italic>
###xml 230 236 <span type="species:ncbi:9913">bovine</span>
###xml 581 587 <span type="species:ncbi:10090">murine</span>
ECM = extracellular matrix; EGF = epidermal growth factor; EMT = epithelial-mesenchymal transitions; ERK = extracellular signal-regulated kinase; FACS = fluorescence-activated cell sorter; FAK = focal adhesion kinase; FBS = fetal bovine serum; GFP = green fluorescent protein; GST = glutathione S-transferase; IRES = internal ribosomal entry site; MAPK = mitogen-activated protein kinase; MEC = mammary epithelial cell; PBS = phosphate-buffered saline; PCR = polymerase chain reaction; PI3K = phosphoinositol-3 kinase; PMA = 4alpha-phorbol 12-myristate 13-acetate; pMSCV = plasmid murine stem cell virus; PTK = protein tyrosine kinase; RGD = arginine-glycine-aspartic acid; RTK = receptor tyrosine kinase; siRNA = small interfering RNA; TbetaR = TGF-beta receptor; TGF = transforming growth factor; WT = wild type; YFP = yellow fluorescent protein.
###end p 79
###begin title 80
Competing interests
###end title 80
###begin p 81
The authors declare that they have no competing interests.
###end p 81
###begin title 82
Authors' contributions
###end title 82
###begin p 83
AJG participated in designing the study, acquiring data, interpreting data, analyzing data, and preparing the manuscript. WPS participated in designing the study, interpreting data, and preparing the manuscript.
###end p 83
###begin title 84
Acknowledgements
###end title 84
###begin p 85
###xml 8 10 5 7 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1 </sub>
TGF-beta1 was generously provided by R&D Systems Inc. Prolactin was generously provided by the National Hormone and Peptide Program (NHPP) at the National Institutes of Health (NIH). Members of the Schiemann Laboratory are thanked for critical reading of the manuscript. We also thank William Townend, Shirley Sobus, and Joshua Loomis for expertise and help provided on studies performed in the Cytometry Core Facility at the National Jewish Medical and Research Center. A special thanks goes to Ian Hardy for help in the analysis of FACS data. Support was provided in part by the National Institutes of Health (CA095519 and CA114039) and the Concern Foundation to WPS.
###end p 85
###begin article-title 86
Mechanisms of TGF-beta signaling from cell membrane to the nucleus
###end article-title 86
###begin article-title 87
p38 mitogen-activated protein kinase is required for TGFbeta-mediated fibroblastic transdifferentiation and cell migration
###end article-title 87
###begin article-title 88
Phosphatidylinositol 3-kinase function is required for transforming growth factor b-mediated epithelial to mesenchymal transition and cell migration
###end article-title 88
###begin article-title 89
TGF-beta-induced apoptosis is mediated by the adapter protein Daxx that facilitates JNK activation
###end article-title 89
###begin article-title 90
Genetic programs of epithelial cell plasticity directed by transforming growth factor-beta
###end article-title 90
###begin article-title 91
Smad-dependent and Smad-independent pathways in TGF-beta family signalling
###end article-title 91
###begin article-title 92
###xml 0 15 <span type="species:ncbi:10090">Transgenic mice</span>
Transgenic mice overexpressing a dominant-negative mutant type II transforming growth factor beta receptor show enhanced tumorigenesis in the mammary gland and lung in response to the carcinogen 7,12-dimethylbenz-[a]-anthracene
###end article-title 92
###begin article-title 93
TGF-beta signaling in tumor suppression and cancer progression
###end article-title 93
###begin article-title 94
TGF-beta switches from tumor suppressor to prometastatic factor in a model of breast cancer progression
###end article-title 94
###begin article-title 95
###xml 60 64 <span type="species:ncbi:10090">mice</span>
Lifetime exposure to a soluble TGF-beta antagonist protects mice against metastasis without adverse side effects
###end article-title 95
###begin article-title 96
Leaving the neighborhood: molecular mechanisms involved during epithelial-mesenchymal transition
###end article-title 96
###begin article-title 97
###xml 43 48 <span type="species:ncbi:9606">human</span>
Role of transforming growth factor beta in human disease
###end article-title 97
###begin article-title 98
TGFbeta signaling in growth control, cancer, and heritable disorders
###end article-title 98
###begin article-title 99
###xml 31 33 28 30 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1 </sub>
Transforming growth factor-beta1 mediates epithelial to mesenchymal transdifferentiation through a RhoA-dependent mechanism
###end article-title 99
###begin article-title 100
Raf induces TGFbeta production while blocking its apoptotic but not invasive responses: a mechanism leading to increased malignancy in epithelial cells
###end article-title 100
###begin article-title 101
Activation of the Erk pathway is required for TGF-beta1-induced EMT in vitro
###end article-title 101
###begin article-title 102
TGF-beta signaling: positive and negative effects on tumorigenesis
###end article-title 102
###begin article-title 103
Regulation of cell adhesion receptors by transforming growth factor-beta. Regulation of vitronectin receptor and LFA-1
###end article-title 103
###begin article-title 104
Integrin-mediated signal transduction pathways
###end article-title 104
###begin article-title 105
Src kinase activation by direct interaction with the integrin beta cytoplasmic domain
###end article-title 105
###begin article-title 106
Focal adhesion kinase in integrin-mediated signaling
###end article-title 106
###begin article-title 107
Signaling through focal adhesion kinase
###end article-title 107
###begin article-title 108
Integrin signalling during tumour progression
###end article-title 108
###begin article-title 109
FAK integrates growth-factor and integrin signals to promote cell migration
###end article-title 109
###begin article-title 110
Role of integrins in cell invasion and migration
###end article-title 110
###begin article-title 111
Integrin expression in breast cancer cytology: a novel predictor of axillary metastasis
###end article-title 111
###begin article-title 112
Role of integrins in cancer: survey of expression patterns
###end article-title 112
###begin article-title 113
###xml 13 14 10 11 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1</sub>
###xml 36 41 <span type="species:ncbi:9606">human</span>
Integrin beta1-mediated invasion of human breast cancer cells: an ex vivo assay for invasiveness
###end article-title 113
###begin article-title 114
###xml 111 113 108 110 <sub xmlns:xlink="http://www.w3.org/1999/xlink">3 </sub>
###xml 40 46 <span type="species:ncbi:10090">murine</span>
Antitumor activity of bacteriophages in murine experimental cancer models caused possibly by inhibition of beta3 integrin signaling pathway
###end article-title 114
###begin article-title 115
###xml 43 48 <span type="species:ncbi:9606">human</span>
Integrin activation controls metastasis in human breast cancer
###end article-title 115
###begin article-title 116
beta3 integrin expression increases breast carcinoma cell responsiveness to the malignancy-enhancing effects of osteopontin
###end article-title 116
###begin article-title 117
Integrin beta1 signaling is necessary for transforming growth factor-b activation of p38MAPK and epithelial plasticity
###end article-title 117
###begin article-title 118
Myofibroblast differentiation by transforming growth factor-beta1 is dependent on cell adhesion and integrin signaling via focal adhesion kinase
###end article-title 118
###begin article-title 119
Trans-dominant inhibition of integrin function
###end article-title 119
###begin article-title 120
Context-specific effects of fibulin-5 (DANCE/EVEC) on cell proliferation, motility, and invasion: fibulin-5 is induced by TGF-beta and affects protein kinase cascades
###end article-title 120
###begin article-title 121
SPARC inhibits epithelial cell proliferation in part through stimulation of the transforming growth factor-beta-signaling system
###end article-title 121
###begin article-title 122
TGF-beta type I receptor/ALK-5 and Smad proteins mediate epithelial to mesenchymal transdifferentiation in NMuMG breast epithelial cells
###end article-title 122
###begin article-title 123
The use of cystatin C to inhibit epithelial-mesenchymal transition and morphological transformation stimulated by transforming growth factor-beta
###end article-title 123
###begin article-title 124
TGF-beta receptor-activated p38 MAP kinase mediates Smad-independent TGF-beta responses
###end article-title 124
###begin article-title 125
A rapid in vitro assay for quantitating the invasive potential of tumor cells
###end article-title 125
###begin article-title 126
Loss of functional cell surface transforming growth factor beta (TGF-beta) type 1 receptor correlates with insensitivity to TGF-beta in chronic lymphocytic leukemia
###end article-title 126
###begin article-title 127
###xml 161 166 <span type="species:ncbi:9606">human</span>
alphavbeta3 integrin interacts with the transforming growth factor beta (TGFbeta) type II receptor to potentiate the proliferative effects of TGFbeta1 in living human lung fibroblasts
###end article-title 127
###begin article-title 128
The transforming growth factor beta receptors types I, II, and III form hetero-oligomeric complexes in the presence of ligand
###end article-title 128
###begin article-title 129
###xml 23 28 <span type="species:ncbi:9606">human</span>
Phosphorylation of the human leukemia inhibitory factor (LIF) receptor by mitogen-activated protein kinase and the regulation of LIF receptor function by heterologous receptor activation
###end article-title 129
###begin article-title 130
A deletion in the gene for transforming growth factor b type I receptor abolishes growth regulation by transforming growth factor b in a cutaneous T-cell lymphoma
###end article-title 130
###begin article-title 131
The organizing principle: microenvironmental influences in the normal and malignant breast
###end article-title 131
###begin article-title 132
Regulation of mammary gland branching morphogenesis by the extracellular matrix and its remodeling enzymes
###end article-title 132
###begin article-title 133
Tumor-stroma interactions
###end article-title 133
###begin article-title 134
Two conformations of the integrin A-domain (I-domain): a pathway for activation?
###end article-title 134
###begin article-title 135
Integrin activation takes shape
###end article-title 135
###begin article-title 136
Integrin-mediated cell adhesion: the extracellular face
###end article-title 136
###begin article-title 137
Positional control of cell fate through joint integrin/receptor protein kinase signaling
###end article-title 137
###begin article-title 138
Src activation is not necessary for transforming growth factor (TGF)-beta-mediated epithelial to mesenchymal transitions (EMT) in mammary epithelial cells. PP1 directly inhibits TGF-beta receptors I and II
###end article-title 138
###begin article-title 139
Regulation of Par6 by extracellular signals
###end article-title 139
###begin article-title 140
###xml 56 61 <span type="species:ncbi:9606">human</span>
Malignant MCF10CA1 cell lines derived from premalignant human breast epithelial MCF10AT cells
###end article-title 140
###begin article-title 141
Cytostatic and apoptotic actions of TGF-b in homeostasis and cancer
###end article-title 141
###begin article-title 142
The adaptor molecule Disabled-2 links the transforming growth factor beta receptors to the Smad pathway
###end article-title 142
###begin article-title 143
Disabled-2 (Dab2) is required for transforming growth factor beta-induced epithelial to mesenchymal transition (EMT)
###end article-title 143
###begin article-title 144
Mechanism of activation of the TGF-beta receptor
###end article-title 144
###begin article-title 145
Positive and negative regulation of type II TGF-beta receptor signal transduction by autophosphorylation on multiple serine residues
###end article-title 145
###begin article-title 146
The type II transforming growth factor-beta receptor autophosphorylates not only on serine and threonine but also on tyrosine residues
###end article-title 146
###begin article-title 147
###xml 81 83 78 80 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1 </sub>
Involvement of EGF receptor and c-Src in the survival signals induced by TGF-beta1 in hepatocytes
###end article-title 147
###begin article-title 148
###xml 57 58 54 55 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1</sub>
Involvement of c-Src kinase in the regulation of TGF-beta1-induced apoptosis
###end article-title 148
###begin article-title 149
###xml 91 94 <span type="species:ncbi:10116">rat</span>
Transforming growth factor-beta activates both pro-apoptotic and survival signals in fetal rat hepatocytes
###end article-title 149
###begin article-title 150
###xml 143 148 <span type="species:ncbi:9606">human</span>
Transforming growth factor-beta-dependent activation of Smad2/3 and up-regulation of PAI-1 expression is negatively regulated by Src in SKOV-3 human ovarian cancer cells
###end article-title 150
###begin article-title 151
Transforming growth factor beta (TGF-beta)-Smad target gene protein tyrosine phosphatase receptor type kappa is required for TGF-beta function
###end article-title 151
###begin article-title 152
Recognition and regulation of primary-sequence motifs by signaling modular domains
###end article-title 152
###begin article-title 153
TGF-beta and the Smad signaling pathway support transcriptomic reprogramming during epithelial-mesenchymal cell transition
###end article-title 153
###begin title 154
Figures and Tables
###end title 154
###begin p 155
###xml 8 10 5 7 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1 </sub>
###xml 51 52 44 45 <sub xmlns:xlink="http://www.w3.org/1999/xlink">v</sub>
###xml 56 58 46 48 <sub xmlns:xlink="http://www.w3.org/1999/xlink">3 </sub>
###xml 159 161 146 148 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1 </sub>
###xml 207 211 194 198 <bold xmlns:xlink="http://www.w3.org/1999/xlink">(a) </bold>
###xml 333 334 316 317 <sub xmlns:xlink="http://www.w3.org/1999/xlink">v</sub>
###xml 338 340 318 320 <sub xmlns:xlink="http://www.w3.org/1999/xlink">3 </sub>
###xml 396 397 372 373 <sub xmlns:xlink="http://www.w3.org/1999/xlink">v</sub>
###xml 401 403 374 376 <sub xmlns:xlink="http://www.w3.org/1999/xlink">3 </sub>
###xml 537 541 510 514 <bold xmlns:xlink="http://www.w3.org/1999/xlink">(b) </bold>
###xml 645 647 613 615 <sub xmlns:xlink="http://www.w3.org/1999/xlink">v </sub>
###xml 655 657 620 622 <sub xmlns:xlink="http://www.w3.org/1999/xlink">3 </sub>
###xml 945 947 904 906 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1 </sub>
###xml 958 962 917 921 <bold xmlns:xlink="http://www.w3.org/1999/xlink">(c) </bold>
###xml 966 968 922 924 <sub xmlns:xlink="http://www.w3.org/1999/xlink">3 </sub>
###xml 1056 1058 1009 1011 <sub xmlns:xlink="http://www.w3.org/1999/xlink">3 </sub>
###xml 1373 1374 1318 1319 <sub xmlns:xlink="http://www.w3.org/1999/xlink">v</sub>
###xml 1380 1381 1322 1323 <sub xmlns:xlink="http://www.w3.org/1999/xlink">3</sub>
###xml 1391 1393 1330 1332 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1 </sub>
TGF-beta1 mediated EMT increases cell surface alphavbeta3 integrin expression in NMuMG cells. NMuMG cells were incubated in the absence or presence of TGF-beta1 (5 ng/ml) for 0-36 hours and assayed for EMT. (a) Alterations in actin cytoskeletal architecture were visualized by direct rhodamine-phalloidin immunofluorescence and alphavbeta3 integrin by indirect immunofluorescence using anti-alphavbeta3 integrin (LM609) antibodies. Shown are representative images from a single experiment that was repeated twice with identical results. (b) Detergent-solubilized whole cell extracts (50 mug/lane) were prepared to analyze expression of the alphav and beta3 integrin subunits by immunoblotting. Differences in protein loading were monitored by reprobing striped blots with anti-ERK1/2 antibodies because, unlike the increase in beta-actin expression observed (data not shown) ERK1/2 expression was unaltered in NMuMG cells in response to TGF-beta1 treatment. (c) beta3 Integrin deficient NMuMG cells were generated by siRNA transfection. The effects of beta3 integrin deficiency on TGF-beta mediated EMT was visualized by direct FITC-phalloidin immunofluorescence. Shown are representative images from a single experiment that was repeated twice with identical results. Detergent-solubilized whole cell extracts (50 mug/lane) were prepared to analyze expression of the alphav, beta3, and beta1 integrin subunits by immunoblotting. Differences in protein loading were monitored by reprobing striped blots with anti-beta-actin antibodies. EMT, epithelial-mesenchymal transitions; ERK, extracellular signal-regulated kinase; siRNA, small interfering RNA; TGF, transforming growth factor.
###end p 155
###begin p 156
###xml 8 10 5 7 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1 </sub>
###xml 35 37 29 31 <sub xmlns:xlink="http://www.w3.org/1999/xlink">3 </sub>
###xml 175 177 163 165 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1 </sub>
###xml 300 306 288 294 <bold xmlns:xlink="http://www.w3.org/1999/xlink">(a,b) </bold>
###xml 315 317 300 302 <sub xmlns:xlink="http://www.w3.org/1999/xlink">3 </sub>
###xml 320 324 305 309 <bold xmlns:xlink="http://www.w3.org/1999/xlink">(b) </bold>
###xml 333 335 315 317 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1 </sub>
TGF-beta1 mediated EMT induces beta3 integrin:TbetaR-II complex formation on the cell surface of NMuMG cells. NMuMG cells were incubated in the absence or presence of TGF-beta1 (5 ng/ml) for 0-30 hours to induce EMT. Detergent-solubilized whole cell extracts (1 mg/tube) were immunoprecipitated with (a,b) anti-beta3 or (b) anti-beta1 integrin antibodies, and subsequently immunoblotted with anti-TbetaR-II antibodies. Shown are representative immunoblots from a single experiment that was repeated twice with identical results. EMT, epithelial-mesenchymal transitions; TbetaR; TGF receptor; TGF, transforming growth factor; WCE, whole cell extracts.
###end p 156
###begin p 157
###xml 4 6 1 3 <sub xmlns:xlink="http://www.w3.org/1999/xlink">3 </sub>
###xml 160 162 154 156 <sub xmlns:xlink="http://www.w3.org/1999/xlink">3 </sub>
###xml 223 227 217 221 <bold xmlns:xlink="http://www.w3.org/1999/xlink">(a) </bold>
###xml 331 333 320 322 <sub xmlns:xlink="http://www.w3.org/1999/xlink">v </sub>
###xml 341 343 327 329 <sub xmlns:xlink="http://www.w3.org/1999/xlink">3 </sub>
###xml 523 527 503 507 <bold xmlns:xlink="http://www.w3.org/1999/xlink">(b) </bold>
###xml 590 592 567 569 <sub xmlns:xlink="http://www.w3.org/1999/xlink">3 </sub>
###xml 620 622 593 595 <sub xmlns:xlink="http://www.w3.org/1999/xlink">v </sub>
###xml 709 711 679 681 <sub xmlns:xlink="http://www.w3.org/1999/xlink">3 </sub>
###xml 739 741 705 707 <sub xmlns:xlink="http://www.w3.org/1999/xlink">v </sub>
###xml 784 786 747 749 <sub xmlns:xlink="http://www.w3.org/1999/xlink">3 </sub>
###xml 795 797 754 756 <sub xmlns:xlink="http://www.w3.org/1999/xlink">v </sub>
###xml 928 932 887 891 <bold xmlns:xlink="http://www.w3.org/1999/xlink">(c) </bold>
###xml 950 952 906 908 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1 </sub>
###xml 1026 1028 979 981 <sub xmlns:xlink="http://www.w3.org/1999/xlink">3 </sub>
###xml 1333 1335 1280 1282 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1 </sub>
###xml 1400 1402 1338 1340 <sub xmlns:xlink="http://www.w3.org/1999/xlink">3 </sub>
###xml 1453 1454 1388 1389 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1</sub>
###xml 1498 1500 1430 1432 <sub xmlns:xlink="http://www.w3.org/1999/xlink">3 </sub>
###xml 568 573 <span type="species:ncbi:9606">human</span>
###xml 699 704 <span type="species:ncbi:9606">human</span>
###xml 728 733 <span type="species:ncbi:10090">mouse</span>
beta3 Integrin overexpression in NMuMG cells. NMuMG cells were engineered by bi-cistronic retroviral transduction to stably express GFP alone (control), WT beta3 integrin (WT) and GFP, or its inactive mutant D119A and GFP. (a) Detergent-solubilized whole cell extracts (50 mug/lane) were prepared to analyze expression of the alphav and beta3 integrin subunits, and of TbetaR-II. Differences in protein loading were monitored by immunoblotting ERK1/2, whose expression in NMuMG cells was not altered by TGF-beta treatment. (b) The percentage of NMuMG cells expressing human recombinant beta3 integrin or endogenous alphav integrin was determined by FACS analysis of cells incubated with either anti-human beta3 integrin or anti-mouse alphav integrin antibodies. Histograms depict beta3 and alphav expression only in GFP-positive NMuMG cells and are from a representative experiment that was repeated twice with similar results. (c) Iodinated TGF-beta1 was bound and chemically cross-linked to control (GFP), WT, and D119A beta3 integrin expressing cells. Cytokine:receptor complexes were isolated by immunoprecipitation with anti-TbetaR-II antibodies, fractionated through 7.5% SDS-PAGE gels, and immobilized electrophoretically to nitrocellulose membranes. The upper panel shows a representative phosphor image of iodinated TGF-beta1 bound to TbetaR-I and TbetaR-II. The middle panel shows that beta3 integrin was present in isolated iodinated TGF-beta1:receptor complexes as detected by anti-beta3 integrin Western blot analysis of anti-TbetaR-II immunocomplexes. Differences in protein loading were monitored by probing detergent-solubilized whole cell extracts (50 mug/lane) with anti-ERK1/2 antibodies (bottom panel). BXL, binding and cross-linking; ERK, extracellular signal-regulated kinase; GFP, green fluorescent protein; WT, wild type; TbetaR, TGF receptor; TGF, transforming growth factor; WCE, whole cell extracts.
###end p 157
###begin p 158
###xml 4 6 1 3 <sub xmlns:xlink="http://www.w3.org/1999/xlink">3 </sub>
###xml 68 72 62 66 <bold xmlns:xlink="http://www.w3.org/1999/xlink">(a) </bold>
###xml 87 89 78 80 <sub xmlns:xlink="http://www.w3.org/1999/xlink">3 </sub>
###xml 169 171 157 159 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1 </sub>
###xml 444 448 432 436 <bold xmlns:xlink="http://www.w3.org/1999/xlink">(b) </bold>
###xml 463 465 448 450 <sub xmlns:xlink="http://www.w3.org/1999/xlink">3 </sub>
###xml 560 562 542 544 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1 </sub>
###xml 1015 1017 995 997 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
beta3 Integrin enhances MAPK activation by TGF-beta in NMuMG cells. (a) Control or beta3 integrin expressing NMuMG cells were serum starved for 4 hours prior to TGF-beta1 stimulation (5 ng/ml) for 0-120 min. Afterward, the activation status of Smad2, ERK1/2, and p38 MAPK was determined by immunoblot analysis using phospho-specific antibodies. Reprobing stripped membranes with anti-ERK1/2 antibodies monitored differences in protein loading. (b) Control or beta3 integrin-expressing NMuMG cells were serum starved for 4 hours before stimulation with TGF-beta1 (5 ng/ml), prolactin (100 ng/ml), PMA (10 ng/ml), or EGF (100 ng/ml) for 30 min. Afterward, the activation status of p38 MAPK was determined by immunoblot analysis using phospho-specific antibodies. Reprobing stripped membranes with anti-pan p38 MAPK antibodies was used to monitor differences in protein loading. Accompanying graphs depict the mean (+/- standard error) fold increase of p38 MAPK stimulation observed in three independent experiments (*P < 0.05). EGF, epidermal growth factor; ERK, extracellular signal-regulated kinase; MAPK, mitogen-activated protein kinase; PMA, 4alpha-phorbol 12-myristate 13-acetate; TGF, transforming growth factor.
###end p 158
###begin p 159
###xml 4 6 1 3 <sub xmlns:xlink="http://www.w3.org/1999/xlink">3 </sub>
###xml 133 137 124 128 <bold xmlns:xlink="http://www.w3.org/1999/xlink">(a) </bold>
###xml 169 171 157 159 <sub xmlns:xlink="http://www.w3.org/1999/xlink">3 </sub>
###xml 261 263 246 248 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1 </sub>
###xml 313 314 298 299 <sup xmlns:xlink="http://www.w3.org/1999/xlink">3</sup>
###xml 473 474 456 457 <sup xmlns:xlink="http://www.w3.org/1999/xlink">3</sup>
###xml 531 535 514 518 <bold xmlns:xlink="http://www.w3.org/1999/xlink">(b) </bold>
###xml 557 559 537 539 <sub xmlns:xlink="http://www.w3.org/1999/xlink">3 </sub>
###xml 678 680 655 657 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1 </sub>
###xml 851 853 820 822 <sub xmlns:xlink="http://www.w3.org/1999/xlink">3 </sub>
###xml 886 890 855 859 <bold xmlns:xlink="http://www.w3.org/1999/xlink">(c) </bold>
###xml 946 948 912 914 <sub xmlns:xlink="http://www.w3.org/1999/xlink">3 </sub>
###xml 1246 1250 1212 1216 <bold xmlns:xlink="http://www.w3.org/1999/xlink">(d) </bold>
###xml 1282 1284 1245 1247 <sub xmlns:xlink="http://www.w3.org/1999/xlink">3 </sub>
###xml 1437 1439 1394 1396 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1 </sub>
beta3 Integrin expression blocks TGF-beta stimulated growth arrest but enhances TGF-beta stimulated invasion and EMT in NMuMG cells. (a) Control (GFP), WT, or D119A beta3 integrin expressing NMuMG cells were stimulated with increasing concentrations of TGF-beta1 for 48 hours. Cellular DNA was radiolabeled with [3H]thymidine and quantified by scintillation counting. Data are the means (+/- standard error) of three independent experiments presented as the percentage of [3H]thymidine incorporation normalized to untreated cells. (b) Control (GFP) and beta3 integrin expressing NMuMG cells were allowed to invade through Matrigel matrices in the absence or presence of TGF-beta1 (5 ng/ml) for 36 hours. Values are the mean (+/- standard error) of three independent experiments presented as the percentage invasion relative to TGF-beta stimulated beta3 integrin expressing NMuMG cells. (c) The cell morphology of control (GFP), WT, and D119A beta3 integrin expressing NMuMG cells was monitored by phase contrast microscopy, and alterations in actin cytoskeletal architecture was visualized by direct rhodamine-phalloidin immunofluorescence. Shown are representative images from a single experiment that was repeated twice with identical results. (d) Control (GFP), WT, or D119A beta3 integrin expressing NMuMG cells were transiently transfected with pSBE-luciferase and pCMV-beta-gal cDNAs, and subsequently were stimulated with TGF-beta1 (5 ng/ml) for 24 hours. Afterward, luciferase and beta-gal activities contained in detergent-solubilized cell extracts were measured. Values are the mean (+/- standard error) luciferase activities observed in three independent experiments normalized to maximal reporter gene expression measured in unstimulated cells. EMT, epithelial-mesenchymal transitions; GFP, green fluorescent protein; TGF, transforming growth factor; WT, wild type; SBE, Smad binding element.
###end p 159
###begin p 160
###xml 82 86 79 83 <bold xmlns:xlink="http://www.w3.org/1999/xlink">(a) </bold>
###xml 142 144 136 138 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1 </sub>
###xml 181 183 172 174 <sub xmlns:xlink="http://www.w3.org/1999/xlink">3 </sub>
###xml 350 352 338 340 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1 </sub>
###xml 526 528 511 513 <sub xmlns:xlink="http://www.w3.org/1999/xlink">3 </sub>
###xml 792 794 768 770 <sub xmlns:xlink="http://www.w3.org/1999/xlink">3 </sub>
###xml 926 930 899 903 <bold xmlns:xlink="http://www.w3.org/1999/xlink">(b) </bold>
###xml 945 947 915 917 <sub xmlns:xlink="http://www.w3.org/1999/xlink">3 </sub>
###xml 1097 1099 1061 1063 <sub xmlns:xlink="http://www.w3.org/1999/xlink">3 </sub>
###xml 1267 1271 1231 1235 <bold xmlns:xlink="http://www.w3.org/1999/xlink">(c) </bold>
###xml 2013 2017 1963 1967 <bold xmlns:xlink="http://www.w3.org/1999/xlink">(d) </bold>
###xml 2467 2468 2411 2412 <italic xmlns:xlink="http://www.w3.org/1999/xlink">S</italic>
Dual receptor activation induces Src mediated TbetaR-II tyrosine phosphorylation. (a) GFP-expressing NMuMG cells were stimulated with TGF-beta1 (5 ng/ml) for 36 hours to induce beta3 integrin expression and EMT. Afterward, the cells were dissociated and re-plated either onto plastic or vitronectin-coated wells in the absence or presence of TGF-beta1 (5 ng/ml) for 5 min. Afterward, detergent-solubilized whole cell extracts were prepared (1 mg/tube) and subsequently immunoprecipitated with anti-phosphotyrosine or anti-beta3 integrin antibodies as indicated. The presence of TbetaR-II in precipitated immunocomplexes was determined by Western blotting with anti-TbetaR-II antibodies. Differences in protein loading were monitored by immunoblotting whole cell extracts (50 mg/lane) for beta3 integrin and TbetaR-II. Shown are representative immunoblots from a single experiment that was repeated twice with similar results. (b) Resting WT beta3 integrin-expressing NMuMG cells were dissociated and re-plated as above. Afterward, TbetaR-II tyrosine phosphorylation and complex formation with beta3 integrin was determined by immunoblotting as above. Shown are representative immunoblots from a single experiment that was repeated three times with identical results. (c) Active recombinant Src (1 unit/reaction) or FAK (0.2 mug/reaction) kinases were added to protein kinase reaction mixtures containing 1 mug/tube of either kinase active (WT) or inactive (K277R) GST-TbetaR-II. Phosphorylation reactions were stopped after 30 min and the phosphorylation status of TbetaR-II was determined by immunoprecipitation of diluted protein kinase reaction mixtures with anti-TbetaR-II antibodies. Afterward, immobilized immunocomplexes were probed sequentially with anti-phosphotyrosine antibodies, followed by anti-TbetaR-II antibodies as indicated (*autophosphorylated recombinant Src; **autophosphorylated recombinant FAK). Data are from a representative experiment that was repeated three times with similar results. (d) Recombinant Src and FAK were incubated in protein kinase assay buffer for 30 min at 30degreesC. The data show the autophosphorylation on tyrosine residues of recombinant Src (*) and FAK (**) as determined by immunoblotting with anti-phosphotyrosine antibodies. Data are from a representative experiment that was repeated at least three times with similar results. EMT, epithelial-mesenchymal transitions; FAK, focal adhesion kinase; GST, glutathione S-transferase; TbetaR, TGF-beta receptor; TGF, transforming growth factor; WCE, whole cell extracts; WT, wild type.
###end p 160
###begin p 161
###xml 73 77 70 74 <bold xmlns:xlink="http://www.w3.org/1999/xlink">(a) </bold>
###xml 219 221 211 213 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1 </sub>
###xml 587 591 576 580 <bold xmlns:xlink="http://www.w3.org/1999/xlink">(b) </bold>
###xml 606 608 592 594 <sub xmlns:xlink="http://www.w3.org/1999/xlink">3 </sub>
###xml 669 671 652 654 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1 </sub>
###xml 1150 1154 1128 1132 <bold xmlns:xlink="http://www.w3.org/1999/xlink">(c) </bold>
###xml 1161 1163 1136 1138 <sub xmlns:xlink="http://www.w3.org/1999/xlink">3 </sub>
###xml 1902 1903 1870 1871 <italic xmlns:xlink="http://www.w3.org/1999/xlink">S</italic>
Src inhibition blocks TbetaR-II tyrosine phosphorylation in NMuMG cells. (a) NMuMG cells were pretreated for 60 min with either PP2 (10 mumol/l) or SU6656 (10 mumol/l). Afterward, the cells were stimulated with TGF-beta1 (5 ng/ml) for 20 min, and subsequently were lysed and immunoprecipitated (1 mg/tube) with anti-TbetaR-II antibodies. The resulting immunocomplexes were used to phosphorylate recombinant GST-Smad3, which was visualized by immunoblotting with anti-phospho-Smad2 antibodies. Data are from a representative experiment that was repeated three times with similar results. (b) Control or beta3 integrin expressing NMuMG cells were stimulated with TGF-beta1 (5 ng/ml) in the absence or presence the Src inhibitor PP2 (10 mumol/l), as indicated. Afterward, detergent-solubilized whole cell extracts were prepared, immunoprecipitated, and subjected to Western blot analysis either with anti-phosphotyrosine (2 mg WCE/tube) or anti-TbetaR-II (1 mg WCE/tube) antibodies as indicated. Differences in protein loading were monitored by probing detergent-solubilized whole cell extracts (50 mug/lane) with anti-ERK1/2 antibodies (bottom panel). (c) WT beta3 integrin expressing NMuMG cells were transiently transfected with cDNAs encoding either constitutively active (CA) or dominant negative (DN) Src. Afterward, detergent solubilized whole cell extracts were prepared, immunoprecipitated with anti-phosphotyrosine (1 mg WCE/tube), and subjected to WB analysis with anti-TbetaR-II antibodies. Total Src expression was monitored by probing detergent solubilized whole cell extracts (50 mug/lane) with anti-Src antibodies, whereas exogenous Src expression was confirmed by reprobing stripped membranes with anti-Myc antibodies. Differences in protein loading were monitored by probing stripped membranes with anti-TbetaR-II antibodies. ERK, extracellular signal-regulated kinase; GST, glutathione S-transferase; IP, immunoprecipitated; PY, phosphotyrosine; TbetaR, TGF-beta receptor; TGF, transforming growth factor; WB, Western blot; WCE, whole cell extracts; WT, wild type.
###end p 161
###begin p 162
###xml 26 28 23 25 <sub xmlns:xlink="http://www.w3.org/1999/xlink">3 </sub>
###xml 110 114 104 108 <bold xmlns:xlink="http://www.w3.org/1999/xlink">(a) </bold>
###xml 129 131 120 122 <sub xmlns:xlink="http://www.w3.org/1999/xlink">3 </sub>
###xml 209 211 197 199 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1 </sub>
###xml 650 654 636 640 <bold xmlns:xlink="http://www.w3.org/1999/xlink">(b) </bold>
###xml 658 660 641 643 <sub xmlns:xlink="http://www.w3.org/1999/xlink">3 </sub>
###xml 721 723 701 703 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1 </sub>
###xml 1024 1028 1003 1007 <bold xmlns:xlink="http://www.w3.org/1999/xlink">(c) </bold>
###xml 1104 1106 1080 1082 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1 </sub>
###xml 1679 1683 1651 1655 <bold xmlns:xlink="http://www.w3.org/1999/xlink">(d) </bold>
###xml 1718 1720 1687 1689 <sub xmlns:xlink="http://www.w3.org/1999/xlink">3 </sub>
###xml 1738 1740 1704 1706 <sub xmlns:xlink="http://www.w3.org/1999/xlink">3 </sub>
###xml 1866 1868 1829 1831 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1 </sub>
###xml 2017 2021 1978 1982 <bold xmlns:xlink="http://www.w3.org/1999/xlink">(e) </bold>
Src inhibition blocks beta3 integrin and TGF-beta mediated MAPK activation, EMT, and invasion in NMuMG cells. (a) Control or beta3 integrin expressing NMuMG cells were serum starved for 4 hours before TGF-beta1 (5 ng/ml) stimulation in the absence or presence of either PP2 (10 mumol/l) or its inactive counterpart PP3 (10 mumol/l). Afterward, the activation status of ERK1/2 and p38 MAPK was determined by immunoblot analysis using phospho-specific antibodies. Re-probing stripped membranes with anti-ERK1/2 antibodies monitored differences in protein loading. Data are from a representative experiment that was repeated twice with similar results. (b) beta3 Integrin expressing NMuMG cells were stimulated with TGF-beta1 (5 ng/ml) for 36 hours in the absence or presence of PP2 (10 mumol/l). Afterward, alterations in actin cytoskeletal architecture were visualized by direct rhodamine-phalloidin immunofluorescence. Shown are representative images from a single experiment that was repeated twice with identical results. (c) Control (GFP) or DN Src-expressing NMuMG cells were stimulated with TGF-beta1 (5 ng/ml) for 24 hours. Afterward, alterations in actin cytoskeletal architecture were visualized by direct rhodamine-phalloidin immunofluorescence. Total Src expression was monitored by probing detergent-solubilized whole cell extracts (50 mug/lane) with anti-Src antibodies, whereas exogenous Src expression was visualized using anti-Myc antibodies. Immunoblotting stripped membranes with anti-beta-actin antibodies served to monitor differences in protein loading. Shown are representative images from a single experiment that was repeated twice with identical results. (d) Control (GFP), DN Src, CA Src, beta3 integrin, and beta3 integrin/DN Src expressing NMuMG cells were allowed to invade through Matrigel matrices in the absence or presence of TGF-beta1 (5 ng/ml) for 36 hours. Values are the mean (+/- standard error) of three independent experiments presented as the number of cells invaded per well. (e) Src-deficient NMuMG cells were generated by siRNA transfection. The effects of Src deficiency on TGF-beta mediated EMT were visualized by direct FITC-phalloidin immunofluorescence. Shown are representative images from a single experiment that was repeated twice with identical results. Detergent-solubilized whole cell extracts (50 mug/lane) were prepared to monitor Src expression by immunoblotting with anti-Src antibodies. Differences in protein loading were monitored by re-probing striped blots with anti-beta-actin antibodies. CA, constitutively active; DN, dominant negative; ERK, extracellular signal-regulated kinase; GFP, green fluorescent protein; MAPK, mitogen-activated protein kinase; TGF, transforming growth factor; WB, Western blot; WT, wild type.
###end p 162
###begin p 163
###xml 4 6 1 3 <sub xmlns:xlink="http://www.w3.org/1999/xlink">3 </sub>
###xml 107 111 101 105 <bold xmlns:xlink="http://www.w3.org/1999/xlink">(a) </bold>
###xml 245 247 235 237 <sub xmlns:xlink="http://www.w3.org/1999/xlink">3 </sub>
###xml 416 418 400 402 <sub xmlns:xlink="http://www.w3.org/1999/xlink">3 </sub>
###xml 438 442 422 426 <bold xmlns:xlink="http://www.w3.org/1999/xlink">(b) </bold>
###xml 458 462 442 446 <bold xmlns:xlink="http://www.w3.org/1999/xlink">(c) </bold>
###xml 565 567 546 548 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1 </sub>
###xml 741 743 714 716 <sub xmlns:xlink="http://www.w3.org/1999/xlink">3 </sub>
###xml 49 54 <span type="species:ncbi:9606">human</span>
beta3 Integrin expression increases in malignant human MECs and regulates invasion stimulated by TGF-beta. (a) Detergent-solubilized whole cell extracts (100 mug/lane) of MCF10A and MCF10CA1a cells were prepared to analyze expression of the beta3 integrin subunit and FAK by immunoblotting. Differences in protein loading were monitored by probing striped blots with anti-TbetaR-II antibodies. Control (GFP) and beta3 integrin expressing (b) MCF10A cells or (c) MCF10CA1a cells were allowed to invade through Matrigel matrices in the absence or presence of TGF-beta1 (5 ng/ml) for 36 hours. Values are the mean (+/- standard error) of three independent experiments presented as the percentage invasion relative to TGF-beta stimulated WT beta3 integrin expressing cells. FAK, focal adhesion kinase; MEC, mammary epithelial cell; TbetaR, TGF-beta receptor; TGF, transforming growth factor; WT, wild type.
###end p 163

